Introduction {#s1}
============

Embryogenesis and patterning of cell differentiation are facilitated by spatiotemporal activation of multiple signaling pathways. The Hedgehog (Hh) signaling is an evolutionarily conserved system that plays a central role in embryogenesis via regulating cell proliferation and differentiation ([@bib17]). Upon stimulation by ligands, post-translational modification of GLI2 and GLI3 induces the expression of *Gli1*, which is a key amplifier of Hh signaling. These post-translational and transcriptional activations of three GLIs regulate specific and redundant target genes ([@bib31]; [@bib15]). Hence, mutants of Hh components cause typical defects such as skeletal, neural, and retinal abnormalities ([@bib31]).

Unlike other core developmental signaling, vertebrate Hh signaling is uniquely and completely dependent upon primary cilia, which are microtubule-based organelles that are formed during the G~0~ or G~1~ phases of the cell cycle ([@bib14]). Binding of Hh ligands to Patched 1 (PTCH1) on cilia leads to activation and induction of Seven-spanner smoothened (SMO) to the cilia ([@bib45]). Activated SMO leads to recruitment of GLI2 and GLI3 to the cilia tip via inhibition of protein kinase A ([@bib5]; [@bib21]; [@bib58]). This dynamic ciliary trafficking of Hh components is primarily regulated by intraflagellar transport (IFT) ([@bib11]; [@bib7]). Thus, ciliogenesis is indispensable for tissue development, and defects in this process impact the development of multiple organs to cause human and mouse diseases termed 'ciliopathies' ([@bib44]). Accordingly, the typical phenotype observed in some of ciliopathies such as Joubert syndrome is abnormalities of Hh signaling ([@bib1]).

Mutations in a number of different ciliopathy-associated genes often result in alterations of ciliary length ([@bib38]; [@bib44]). Indeed, genetic screenings of *Chlamydomonas*, which is a model organism for ciliogenesis, have identified the ciliopathy-associated genes controlling cilia length to generate the optimal length at steady-state ([@bib57]). Although these abnormalities in ciliary length are thought to be controlled by the balance of assembly and disassembly via IFT and a postulated length sensor, the mechanisms for maintaining the cell-type-specific ciliary length have not been fully elucidated ([@bib19]). In contrast, the ciliary resorption mechanisms for cell cycle re-entry have been thoroughly investigated by such as an experiment of serum re-addition to starved cells, and these mechanisms include the HEF1-AURKA-HDAC6 pathway ([@bib42]), the PLK-KIF2A pathway ([@bib55]), and the NEK2-KIF24 pathway ([@bib24]; [@bib23]) that have been observed to induce disassembly of cilia. On the other hand, the ability of these ciliary resorption factors for cell cycle re-entry to control cilia length at steady-state and during ciliogenesis remains to be elucidated. Hence, identification of novel mammalian factors regulating ciliogenesis and ciliary length control will provide insight into the molecular mechanisms underlying embryogenesis and ciliopathy as well as ciliary functions.

Dual-specificity tyrosine-regulated kinase (DYRK) is a family that belongs to the CMGC group that includes cyclin-dependent kinases ([C]{.ul}DK), mitogen-activated protein kinase ([M]{.ul}APK), glycogen synthase kinase ([G]{.ul}SK), and CDK-like kinase ([C]{.ul}LKs) ([@bib2]). Two isoforms of *Dyrk2* have been identified; long and short forms, the latter lacks a 5' terminal region. In human cancer cells, we have functionally identified DYRK2 as a regulator of p53-induced apoptosis in response to DNA damage ([@bib49]) and of G1/S transition ([@bib51]). During development in lower eukaryotes, MBK2, which is an ortholog of DYRK2 in *Caenorhabditis elegans*, regulates maternal-protein degradation during the oocyte-to-embryo transition via a ubiquitin-dependent mechanism ([@bib40]; [@bib39]; [@bib26]; [@bib61]). While these reports lead us to speculate that DYRK2 must also play important roles in mammalian development, no reports are available regarding the mechanistic role of DYRK2 in vivo.

In the present study, we aim to reveal a function for DYRK2 in mammalian development in vivo. Here, we demonstrate that DYRK2 is a novel regulator of ciliogenesis and is required for normal embryogenesis via activation of Hh signaling during development.

Results {#s2}
=======

*Dyrk2* deficiency cause suppression of Hedgehog signaling during mouse embryogenesis {#s2-1}
-------------------------------------------------------------------------------------

We generated *Dyrk2* knockout mice (*Dyrk2^-/-^*) by eliminating the third exon of the *Dyrk2* genomic locus ([Figure 1---figure supplement 1A--B](#fig1s1){ref-type="fig"}). The absence of DYRK2 protein in homozygous *Dyrk2^-/-^* mice was confirmed ([Figure 1---figure supplement 1C](#fig1s1){ref-type="fig"}). Although the gross morphology of homozygous *Dyrk2^-/-^* embryos appeared normal during early development, multiple defects became obvious during later stages of gestation, and the mice died at or close to birth ([Figure 1A](#fig1){ref-type="fig"}). Specifically, defects in skeletal development were remarkable, and these included a shorter dorsum of the nose ([Figure 1A](#fig1){ref-type="fig"}), cleft palate including hypoplasia of the tongue ([Figure 1B--C](#fig1){ref-type="fig"}), loss of the basisphenoid, basioccipital, and presphenoid bones ([Figure 1D](#fig1){ref-type="fig"}), shorter limbs ([Figure 1E](#fig1){ref-type="fig"}), defects of segmentation of the sternebrae in the sternum ([Figure 1F](#fig1){ref-type="fig"}), and vertebra ([Figure 1G](#fig1){ref-type="fig"}) at embryonic day (E) 18.5. These skeletal defects that included reduction of bone mineralization were observed until E16.5 ([Figure 1H](#fig1){ref-type="fig"}).

![Deletion of DYRK2 shows skeletal defects in mouse development.\
(**A**) Whole embryo gross images of wild-type and homozygous *Dyrk2^-/-^* embryos at birth. (**B, C**) Palatal and tongue abnormalities in *Dyrk2^-/-^* embryos. Gross images of the palate with mandible removed from wild-type and *Dyrk2^-/-^* embryos at E18.5 (**B**), and HE staining from the coronal plane at E13.5 (**C**). Dotted lines in (**B**) and an asterisk in (**C**) indicate cleft of the secondary palate. (**D--H**) Arizarin red and alcian blue staining of the craniofacial skeleton (**D**), forelimbs (**E**), sternum (**F**), and vertebra (**G**) from wild-type and *Dyrk2^-/-^* embryos at E18.5, and whole skeleton staining at E16.5 (**H**). Arrowheads in (**H**) indicate regions that decreasing bone mineralization. bo, basioccipital bone; bs, basisphenoid; h, humerus; r, radius; p, palatal shelves; ps, presphenoid; s, scapula; st, sternebrae; t, tongue; u, ulna. Scale bars, 5 mm.](elife-57381-fig1){#fig1}

As *Dyrk2^-/-^* embryos at E18.5 exhibited a similar phenotype to that observed in response to certain defects in Hh signaling ([@bib31]), we assessed *Gli1*-expression, which is an indicator of Hh signaling activation ([@bib34]). In situ hybridization demonstrated that *Gli1*-expression was decreased in the craniofacial region in *Dyrk2^-/-^* embryos at E14.5 ([Figure 2A](#fig2){ref-type="fig"}). Protein levels of GLI1 were also decreased at E13.5 ([Figure 2B](#fig2){ref-type="fig"}). *Ptch1*-expression, which is another indicator of Hh signaling activation ([@bib47]), was also decreased in *Dyrk2^-/-^* embryos at E13.5, and this was accompanied by a decrease in *Gli1*; however, *Shh*-expression remained unchanged ([Figure 2C](#fig2){ref-type="fig"}). We also observed a repression of *Foxf2*-expression, which is a direct target gene of GLI1 ([@bib8]), in the craniofacial region of *Dyrk2^-/-^* embryos ([Figure 2D--E](#fig2){ref-type="fig"}).

![Deletion of DYRK2 affects activation of Hh signaling in mouse development.\
(**A**) In situ hybridization of *Gli1* in the craniofacial region in wild-type and *Dyrk2^-/-^* embryos from the sagittal plane at E14.5. (**B**) Immunoblotting of GLI1 in extracts from the limbs of wild-type and *Dyrk2^-/-^* embryos at E13.5. GAPDH serves as a loading control. (**C**) qPCR of *Gli1*, *Ptch1*, and *Shh* in the limbs from wild-type and *Dyrk2^-/-^* embryos at E13.5. (**D, E**) Repression of *Foxf2*-expression in the craniofacial region of *Dyrk2^-/-^* mice. (**D**) In situ hybridization of *Foxf2* in the craniofacial region in wild-type and *Dyrk2^-/-^* embryos from the sagittal plane at E14.5. (**E**) qPCR of *Foxf2* in the mandibular arch from wild-type and *Dyrk2^-/-^* embryos at E10.5. Hypoxanthine phosphoribosyltransferase (*Hprt*) in (**C and E**) was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of wild-type. Data are presented as the means ± SEM (*n* = 3 biological replicates). The statistical significance between wild-type and *Dyrk2^-/-^* was determined by the Student's *t*-test. (\*) p\<0.05, (\*\*) p\<0.01. t, tongue; ul, upper lip. Scale bars, 500 µm.\
Figure 2---source data 1.Source data for [Figure 2C and E](#fig2){ref-type="fig"}.](elife-57381-fig2){#fig2}

Loss of genes required for Hh signaling often causes defects in dorsal-ventral neural tube patterning, which is regulated by the SHH morphogen ([@bib6]). Although we investigated the localization patterns of FOXA2, NKX2.2, OLIG2, NKX6.1, and PAX6 at E10.5, we did not observe obvious differences in their expression patterns ([Figure 2---figure supplement 1A](#fig2s1){ref-type="fig"}). Expression of Hh target genes was decreased in *Dyrk2^-/-^* whole embryos at E9.5 ([Figure 2---figure supplement 1B](#fig2s1){ref-type="fig"}). In situ hybridization demonstrated that *Ptch1*-expression was decreased in the mandibular arch in *Dyrk2^-/-^* embryos at E10.5, but remained unchanged in the neural tube ([Figure 2---figure supplement 1C](#fig2s1){ref-type="fig"}). These data showing the maintenance of Hh signal and dorsal-ventral patterning in the neural tube might correspond to a spatiotemporal expression-pattern of *Dyrk2*.

Taken together, *Dyrk2*-deficient embryos exhibit a robust suppression of Hh signaling and possess particular skeletal abnormalities during embryogenesis.

DYRK2 positively regulates Hh signaling {#s2-2}
---------------------------------------

To investigate the defect in Hh signaling in *Dyrk2^-/-^* mice in more detail, we analyzed primary mouse embryonic fibroblasts (MEFs) derived from wild-type and *Dyrk2^-/-^* mice. First, we measured Hh signaling activity in response to stimulation with the SMO agonist SAG. In response to stimulation with SAG, *Gli1* and *Ptch1* expression was increased in wild-type mice as previously reported ([Figure 3A](#fig3){ref-type="fig"}; [@bib34]). In contrast, in *Dyrk2^-/-^* MEFs, inductions of both *Gli1* and *Ptch1* expression by SAG was drastically repressed ([Figure 3A](#fig3){ref-type="fig"}). Consistent with gene expression analyses, the induction of GLI1 protein by SAG stimulation was also suppressed in *Dyrk2^-/-^* MEFs ([Figure 3B](#fig3){ref-type="fig"}). Immunocytostaining for GLI1 following stimulation with SAG demonstrated that the accumulation of GLI1 protein within nuclei was clearly diminished in *Dyrk2^-/-^* MEFs ([Figure 3C](#fig3){ref-type="fig"}). To validate whether these phenotypes observed in *Dyrk2^-/-^* MEFs are due to abnormal differentiation caused by deletion of *Dyrk2* during early embryogenesis, we performed a transient knockdown of *Dyrk2* in wild-type MEFs using two independent short interfering RNAs (siRNAs). Transient knockdown of *Dyrk2* also demonstrated suppression of both the mRNA and protein levels of *Gli1* and *Ptch1* in response to stimulation with SAG ([Figure 3---figure supplement 1A--B](#fig3s1){ref-type="fig"}).

![Deletion of *Dyrk2* suppresses activation of Hh signaling in vitro.\
(**A**) Expression of the Hh target genes *Gli1* and *Ptch1* in wild-type and *Dyrk2^-/-^* MEFs in the absence or presence of 100 nM SAG was measured by qPCR. Data are shown as relative expression to *Hprt*. (**B**) Protein levels of GLI1 and DYRK2 in wild-type and *Dyrk2^-/-^* MEFs in the absence or presence of 100 nM SAG were measured by immuno-blotting. L and S indicate long and short transcriptional isoforms of DYRK2, respectively. (**C**) Wild-type and *Dyrk2^-/-^* MEFs in the absence or presence of 100 nM SAG were immune-cytostained for GLI1 (red). Nuclei were stained with DAPI (blue). Scale bars, 5 µm. (**D**) Expression of *Gli1* and *Ptch1* in *Dyrk2^-/-^* MEFs overexpressing human *DYRK2* or *DYRK2-K251R* (kinase dead) constructs via adenovirus infection was measured by qPCR. Data indicates fold induction of 100 nM SAG against vehicle after normalization to *Hprt*. (**E, F**) Immunoblotting for GLI2 in wild-type and *Dyrk2^-/-^* MEFs in the absence or presence of 100 nM SAG. Protein level as fold changes of GLI2 (**E**) was calculated by comparing protein levels relative to those of wild-type MEFs in the absence of SAG after normalization to the GAPDH loading control in (**F**). Data are presented as the means ± SEM (*n* = 5, 3, and 4 biological replicates per condition in A, D, and F, respectively). The statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. (\*) p\<0.05, (\*\*) p\<0.01.\
Figure 3---source data 1.Source data for [Figure 3A and D](#fig3){ref-type="fig"}.\
Figure 3---source data 2.Source data for [Figure 3F](#fig3){ref-type="fig"}.](elife-57381-fig3){#fig3}

To validate this suppression of Hh signaling by *Dyrk2-*deletion, we performed a transient over-expression experiment using wild-type human *DYRK2* or a *DYRK2-K251R* construct that expresses a kinase dead mutant ([@bib51]; [Figure 3---figure supplement 1C--D](#fig3s1){ref-type="fig"}) in *Dyrk2^-/-^* MEFs using adenovirus infection ([@bib60]). Over-expression of the wild-type *DYRK2* construct restored significant induction of *Gli1* and *Ptch1* expression upon exposure to SAG ([Figure 3D](#fig3){ref-type="fig"}, [Figure 3---figure supplement 1D](#fig3s1){ref-type="fig"}). In sharp contrast, over-expression of the *DYRK2-K251R* construct in *Dyrk2^-/-^* MEFs markedly diminished *Gli1* and *Ptch1* expression ([Figure 3D](#fig3){ref-type="fig"}). Additionally, over-expression of the *DYRK2-K251R* construct slightly increased *Gli1* and *Ptch1* expression in comparison with that of empty vector ([Figure 3D](#fig3){ref-type="fig"}). This kinase-independent effect might be associated with a function of DYRK2 as a scaffold protein ([@bib27]). Taken together, the induction of Hh signaling is drastically suppressed by deletion of *Dyrk2* in a kinase activity-dependent manner.

The key Hh pathway components GLI2 and GLI3 are known to be posttranslationally modified in a manner that is dependent upon Hh ligands ([@bib31]; [@bib15]). In the absence of Hh ligands, the full-length proteins (active forms; GLI2 and GLI3^FL^) are phosphorylated by multiple kinases, leading to proteasomal degradation or truncation into N-terminal repressor forms (GLI3^REP^), respectively ([@bib34]). In this context, we analyzed the endogenous protein levels and states of GLI2 and GLI3. In wild-type MEFs, immunoblotting for GLI2 revealed that full-length form of GLI2 was increased by SAG-stimulation ([Figure 3E--F](#fig3){ref-type="fig"}). In contrast to wild-type MEFs, the increase of GLI2 protein levels by SAG was significantly suppressed in *Dyrk2^-/-^* MEFs ([Figure 3E--F](#fig3){ref-type="fig"}). We also analyzed two forms of GLI3 (GLI3^FL^ and GLI3^REP^). SAG-stimulation suppressed the formation of GLI3^REP^ and decreased the ratio of GLI3^REP^/GLI3^FL^ in wild-type MEFs ([Figure 3---figure supplement 2](#fig3s2){ref-type="fig"}; [@bib34]). In *Dyrk2^-/-^* MEFs, however, we found that the ratio of GLI3^REP^/GLI3^FL^ was marginally suppressed and that no significant differences between the absence or presence of SAG existed ([Figure 3---figure supplement 2D](#fig3s2){ref-type="fig"}). Collectively, these data indicate that the deletion of *Dyrk2* affects the stabilities of GLI2, and marginally GLI3, under SAG-stimulation.

DYRK2 regulates ciliogenesis {#s2-3}
----------------------------

As primary cilia are essential organelles required for signal transduction of vertebrate Hh signaling ([@bib14]), we investigated whether DYRK2 regulates ciliogenesis in MEFs. Immunostaining of acetylated tubulin (a cilia axoneme marker) and γ-tubulin (a basal body marker) demonstrated that the length of primary cilia in *Dyrk2^-/-^* MEFs was significantly longer than that in wild-type MEFs ([Figure 4A](#fig4){ref-type="fig"}). The average cilia length in wild-type MEFs was 1.65 ± 0.03, while it was 3.59 ± 0.08 in *Dyrk2^-/-^* MEFs ([Figure 4B--C](#fig4){ref-type="fig"}). In addition to the increased length, the morphology of primary cilia in *Dyrk2^-/-^* MEFs was often bulged at the tips, tapered, and twisted ([Figure 4A](#fig4){ref-type="fig"}). This elongation and morphological abnormality of primary cilia was similarly observed in response to the transient knockdown of *Dyrk2* by siRNA in wild-type MEFs ([Figure 4---figure supplement 1](#fig4s1){ref-type="fig"}). To investigate whether the regulation of ciliogenesis by DYRK2 is conserved in other species and cell types, we analyzed immortalized human retinal pigment epithelia cells (hTERT-RPE1 cells) that are commonly used to study cilia-assembly and -disassembly. A transient knockdown by si*DYRK2* also induced a significant elongation and morphological abnormality in cilia of these cells ([Figure 4---figure supplement 2](#fig4s2){ref-type="fig"}). In contrast to the length and morphology of primary cilia, no difference was observed on the proportion of ciliated cells in wild-type and *Dyrk2^-/-^* MEFs ([Figure 4---figure supplement 3A--B](#fig4s3){ref-type="fig"}). Similarly, in cell-cycling (KI67-positive) wild-type and *Dyrk2^-/-^* MEFs, there was comparable in the proportion of ciliated cells (ciliated cells in KI67-positive cells is 1 per 199 and 1 per 139 cells in wild-type and *Dyrk2^-/-^* MEFs, respectively) ([Figure 4---figure supplement 3C](#fig4s3){ref-type="fig"}).

![DYRK2 constrains the length of primary cilia.\
(**A--C**) Elongation of primary cilia in *Dyrk2^-/-^* MEFs. Primary cilia of wild-type and *Dyrk2^-/-^* MEFs were immunostained with acetylated-tubulin and gamma-tubulin antibodies. (**B, C**) Measurements of cilia length in wild-type and *Dyrk2^-/-^* MEFs using acetylated-tubulin as a cilia axoneme marker. Cilia lengths are presented as pooled from five MEFs derived from independent embryos of each genotype (**B**) and the average of each MEF (**C**). Data are presented as the means ± SEM (*n* = 5 biological replicates per condition). The statistical significance between wild-type and *Dyrk2^-/-^* was determined by the Student's *t*-test. (\*\*) p\<0.01. (**D**) Scanning electron microscopy showing wild-type and *Dyrk2^-/-^* embryos in the frontonasal prominence at E10.5. (**E**) Immunohistochemistry of primary cilia in wild-type and *Dyrk2^-/-^* embryos. ARL13B was immuno-stained in wild-type and *Dyrk2^-/-^* mesenchymal cells at the craniofacial region at E13.5. Nuclei were stained with DAPI. Scale bars, 5 µm (**A and E**) and 1 µm (**D**).\
Figure 4---source data 1.Source data for [Figure 4B--C](#fig4){ref-type="fig"}.](elife-57381-fig4){#fig4}

To confirm the morphological abnormalities of primary cilia within the tissue, we performed scanning electron microscopy (SEM) on embryos at E10.5. SEM images clearly showed that the cilia of *Dyrk2^-/-^* embryos were significantly elongated, bulged at the tips, and twisted, while those of wild-type embryos were shortened and straight ([Figure 4D](#fig4){ref-type="fig"}). These abnormalities were also observed in several types of cells, including mesenchymal cells ([Figure 4E](#fig4){ref-type="fig"}), chondrocytes, neuroepithelium, and tongue cells (data not shown) in the embryonic craniofacial region at E13.5 as assessed by immunohistochemistry.

These data indicating that deletion of *Dyrk2* causes morphological abnormalities in primary cilia prompted us to determine the subcellular localization of DYRK2. We transfected DYRK2-HaloTag constructs into hTERT-RPE1 cells and induced ciliogenesis by serum-starvation. Immunocytostaining for both anti-HaloTag and anti-DYRK2 revealed that DYRK2 localized at γ-tubulin-positive basal bodies and at the proximal end of the axoneme, namely a transition zone (TZ) ([Figure 5A--B](#fig5){ref-type="fig"}). No signal for anti-HaloTag ([Figure 5C](#fig5){ref-type="fig"}) or anti-DYRK2 (data not shown) was observed in hTERT-RPE1 cells transfected with empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector). Moreover, immuno-positive signals for DYRK2-HaloTag were co-localized with a TZ marker, NPHP1 ([Figure 5D](#fig5){ref-type="fig"}).

![DYRK2 localizes at basal bodies and transition zone (TZ) in primary cilia.\
Cultured hTERT-RPE1 cells were transfected with a mouse DYRK2-HaloTag overexpression construct and immunostained using anti-HaloTag (**A**) or anti-DYRK2 (**B**) with acetylated-tubulin (white) and gamma-tubulin antibodies. (**C**) Cultured hTERT-RPE1 cells transfected with an empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector) and immunostained using anti-HaloTag with acetylated-tubulin (white) and gamma-tubulin antibodies. (**D**) Co-localization of DYRK2 and a TZ marker, NPHP1. Cultured hTERT-RPE1 cells overexpressed with a mouse DYRK2-HaloTag were immunostained using anti-HaloTag, NPHP1 (white), and gamma-tubulin antibodies. Nuclei were stained with DAPI. Scale bars, 5 µm.](elife-57381-fig5){#fig5}

These data indicated that DYRK2 might regulate ciliogenesis at basal bodies and TZ in vivo and in vitro.

Deletion of DYRK2 induces abnormal ciliary trafficking of Hedgehog pathway components {#s2-4}
-------------------------------------------------------------------------------------

In mammals, key regulators of Hh signaling have been demonstrated to be recruited and activated at the cilia upon Hh stimulation ([@bib5]; [@bib21]; [@bib53]; [@bib58]), and disorders in the ciliary trafficking of Hh components cause dysfunction of Hh signaling ([@bib12]). To investigate whether inactivation of Hh signaling in *Dyrk2^-/-^* embryos and MEFs is due to abnormal ciliary trafficking of Hh components, we analyzed the ciliary localization of key regulators such as SMO, GLI2, GLI3, and SuFu. In wild-type MEFs, immuno-positive SMO signals were mostly undetectable or faint in the absence of Hh stimulation, and recruitment to cilia was dependent upon Hh stimulation ([Figure 6A--B](#fig6){ref-type="fig"}), as shown in a previous report ([@bib53]). Similarly, no significant difference in the frequency of SMO recruitment in response to SAG stimulation was observed in *Dyrk2^-/-^* MEFs ([Figure 6A--B](#fig6){ref-type="fig"}).

![Depletion of *Dyrk2* induces abnormal ciliary trafficking of endogenous Hh components.\
Ciliary localization of endogenous SMO, GLI2, and GLI3 in wild-type and *Dyrk2^-/-^* MEFs in the absence or presence of 100 nM SAG. Primary cilia were immuno-stained for SMO (**A**), GLI2 (**C**), or GLI3 (**E**) with ARL13B and gamma-tubulin (white) antibodies. Nuclei were stained with DAPI (blue). The percentage of cells with SMO (**B**) at the cilia or foci of GLI2 (**D**) or GLI3 (**F**) at the cilia tips was determined. Data are presented as the means ± SEM (*n* = 3 biological replicates for each condition;\>110 cells were scored for each experiment). The statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. (\*) p\<0.05, (\*\*) p\<0.01. Scale bars, 5 µm.\
Figure 6---source data 1.Source data for [Figure 6B,D and F](#fig6){ref-type="fig"}.](elife-57381-fig6){#fig6}

We subsequently analyzed the ciliary localization of endogenous GLI2 and GLI3. As shown in a previous report ([@bib53]), in wild-type MEFs, immuno-positive signals for both GLI2 and GLI3 were mostly undetectable or faint in the absence of Hh stimulation, and SAG stimulation increased the presence of GLI2 and GLI3 at cilia tips ([Figure 6C--F](#fig6){ref-type="fig"}). In contrast, in *Dyrk2^-/-^* MEFs, immuno-positive signals for both GLI2 (approximately 75.9% of cilia) and GLI3 (approximately 95.8%) were observed at cilia tip even in the absence of SAG treatment ([Figure 6C--F](#fig6){ref-type="fig"}). Moreover, the intensity of immune-positive signals was markedly increased by SAG-treatment in *Dyrk2^-/-^* MEFs ([Figure 6C,E](#fig6){ref-type="fig"}). These accumulations at cilia tips were frequently observed in *Dyrk2^-/-^* mesenchymal cells in the craniofacial region at E10.5 tissues but were absent in wild-type cells ([Figure 6---figure supplement 1](#fig6s1){ref-type="fig"}). Additionally, localization of SuFu, which forms a complex with both GLI2 and GLI3 ([@bib53]), was disordered in cilia tips in a similar pattern to that of GLI2 and GLI3 ([Figure 6---figure supplement 2A](#fig6s2){ref-type="fig"}). Collectively, ciliary localization of GLI2, GLI3, and SuFu in *Dyrk2^-/-^* MEFs and embryos was clearly disordered and was accumulated at cilia tips. Importantly, the recruitment of GLI2, GLI3, and SuFu in response to SAG stimulation was also observed in *Dyrk2^-/-^* MEFs.

Inhibition of retrograde transport from the tip to the cell body induces accumulation of Hh components and results in abnormal localization of both IFT-A (implicated in retrograde IFT) and IFT-B (implicated in anterograde) ([@bib37]; [@bib36]; [@bib25]). Based on this, we analyzed the ciliary localization of core IFT-A (IFT140) and IFT-B (IFT81 and IFT88) ([@bib33]). In *Dyrk2^-/-^* MEFs, no obvious differences in ciliary localization of IFT140, IFT81, and IFT88 were observed ([Figure 6---figure supplement 2B--D](#fig6s2){ref-type="fig"}).

Activation of mammalian target of rapamycin complex 1 (mTORC1) also induces abnormal trafficking and elongates cilia length ([@bib4]). mTORC1 activation leads to phosphorylation of ribosomal S6 kinase (S6K) and eukaryotic translational initiation factor 4E binding protein (4EBP). In *Dyrk2^-/-^* MEFs, phosphorylation of both S6K and 4EBP was slightly increased ([Figure 6---figure supplement 3A](#fig6s3){ref-type="fig"}); however, treatment with rapamycin, an inhibitor of mTORC1, resulted in no obvious differences in cilia length in *Dyrk2^-/-^* MEFs ([Figure 6---figure supplement 3B--D](#fig6s3){ref-type="fig"}).

Moreover, a centrosome protein CP110 ([@bib13]) and a microtubule severing enzyme, KATANIN p60 ([@bib27]), have been identified as substrates of DYRK2 for proteolysis. In *Dyrk2^-/-^* MEFs, however, no obvious difference in protein levels of both CP110 and KATANIN p60 was observed ([Figure 6---figure supplement 4](#fig6s4){ref-type="fig"}).

Deletion of *Dyrk2* dysregulates the expression of *Aurka* and other cilia-disassembly genes {#s2-5}
--------------------------------------------------------------------------------------------

To understand the molecular mechanisms underlying cilia dysfunction in *Dyrk2^-/-^* mice, we focused on factors that are involved in ciliary length control by incorporating whole-genome RNA sequencing using wild-type and *Dyrk2^-/-^* MEFs ([Figure 7](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1](#fig7s1){ref-type="fig"}). The data were analyzed by multiple testing and according to p-value, false discovery rate (FDR), and ratio (*Dyrk2^-/-^*/wild-type). As a result, the number of identified genes was 53 or 42 that were significantly downregulated (p\<0.005, ratio \<1.5 fold) or upregulated (p\<0.005, ratio \>1.5 fold) in *Dyrk2^-/-^* MEFs, respectively, regardless of the presence or absence of SAG ([Table 1](#table1){ref-type="table"}). Notably, GO and STRING analysis revealed that the 53 downregulated genes in *Dyrk2^-/-^* MEFs were enriched in cell division (GO: 0051301, FDR = 5.17E-40), microtubule cytoskeleton organization (GO:0000226, FDR = 5.23E-15), spindle organization (GO:0007051, FDR = 2.72E-11), mitotic cell cycle checkpoint (GO:0007093, FDR = 3.78E-07), and microtubule-based movement (GO:0007018, FDR = 3.9E-4) ([Figure 7A](#fig7){ref-type="fig"}, [Figure 7---figure supplement 1B](#fig7s1){ref-type="fig"}). These downregulated genes in *Dyrk2^-/-^* MEFs included those related to ciliary resorption mechanisms for proliferation, including the HEF1-AURKA-HDAC6 pathway (*Aurka*, *Plk1*, *Ube2c*, and *Tpx2*) ([@bib42]), the PLK-KIF2A pathway (*Plk1* and *Kif2c*, a family of *Kif2a*) ([@bib55]), and the APC^CDC20^-Nek1 pathway (*Cdc20*) that controls ciliary length ([@bib56]; [@bib20]). We confirmed the downregulation of *Aurka*, *Plk1*, *Ube2c*, *Tpx2, Kif2c,* and *Cdc20* in *Dyrk2^-/-^* MEFs by qPCR ([Figure 7B](#fig7){ref-type="fig"}). To identify a molecule involved in cilia-elongation in *Dyrk2^-/-^* cells, we performed transient knockdown of selected genes using siRNA in wild-type MEFs, and we analyzed cilia length. Notably, we found that knockdown of *Aurka* by two independent siRNAs significantly increases cilia length ([Figure 8](#fig8){ref-type="fig"}). Moreover, we performed a rescue experiment by over-expression of AURKA-EGFP in *Dyrk2^-/-^* MEFs ([Figure 9](#fig9){ref-type="fig"}). Immunostaining and measurement of the cilia length in EGFP- (transfected with pEGFP-C1) or AURKA-EGFP-positive (transfected with *Aurka*/pEGFP-C1) *Dyrk2^-/-^* MEFs demonstrated that elongated cilia in *Dyrk2^-/-^* MEFs were significantly shortened in AURKA-EGFP-positive cells in comparison with EGFP-positive ones ([Figure 9D--G](#fig9){ref-type="fig"}).

![Changes in mRNA expression of genes in *Dyrk2^-/-^* MEFs.\
(**A**) STRING GO analyses of the 53 differentially downregulated genes in *Dyrk2^-/-^* MEFs reveals protein-protein interaction networks. Robust networks for cell division (green, GO: 0051301), microtubule cytoskeleton organization (red, GO:0000226), spindle organization (yellow, GO:0007051), mitotic cell cycle checkpoint function (purple, GO:0007093), and microtubule-based movement (blue, GO:0007018) were extracted. (**B**) Confirmation of downregulation of genes related to ciliary resorption mechanisms in *Dyrk2^-/-^* MEFs by qPCR. *Hprt* was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of wild-type. Data are presented as the means ± SEM (*n* = 3 biological replicates per condition). The statistical significance between wild-type and *Dyrk2^-/-^* MEFs was determined using the Student's *t*-test. (\*) p\<0.05.\
Figure 7---source data 1.Source data for [Figure 7B](#fig7){ref-type="fig"}.](elife-57381-fig7){#fig7}

![Elongation of primary cilia in wild-type MEFs treated with si*Aurka.*\
(**A**) Immunoblotting of AURKA in wild-type and *Dyrk2^-/-^* MEFs. GAPDH serves as a loading control. (**B**) Knockdown efficiency of *Aurka*-expression in wild-type MEFs treated with two independent si*Aurka* for 48 hr was measured by qPCR. *Hprt* was used as an internal standard, and fold change was calculated by comparing expression levels relative to those of siNegative (siNeg.). Data are presented as the means ± SEM (*n* = 3 biological replicates per condition). (**C**) Primary cilia in wild-type cells treated with siNegative (siNeg.) or two independent si*Aurka* were immuno-stained with ARL13B and gamma-tubulin antibodies. Scale bars, 5 µm. (**D, E**) Measurements of cilia length in wild-type MEFs treated with siNeg. or two independent si*Aurka* using ARL13B and acetylated-tubulin as a cilia axoneme marker. Cilia lengths are presented as pooled from four MEFs derived from independent wild-type embryos (**D**) and represent an average of each MEF (**E**). Data are presented as the means ± SEM (*n* = 4 biological replicates per condition). The statistical significance was determined by one-way ANOVA followed by Tukey's multiple comparison test. (\*\*) p\<0.01.\
Figure 8---source data 1.Source data for [Figure 8B and D--E](#fig8){ref-type="fig"}.](elife-57381-fig8){#fig8}

![Reduction of the length of primary cilia in *Dyrk2^-/-^* MEFs by over-expression of AURKA.\
(**A--C**) Immunoblotting by anti-AURKA (**A**), anti-GFP (**B**), and anti-GAPDH (**C**) in cells transfected with pEGFP-C1 or mouse *Aurka*/pEGFP-C1. GAPDH serves as a loading control. (**D, E**) Primary cilia in *Dyrk2^-/-^* MEFs over-expressed with EGFP (**D**) or AURKA-EGFP (**E**) were immunostained with GFP, ARL13B, and gamma-tubulin (white) antibodies. Arrowheads in (**E**) indicate signals for AURKA-EGFP in gamma-tubulin-positive basal body. Scale bars, 5 µm. (**F, G**) Measurements of cilia length in EGFP- or AURKA-EGFP-over-expressed *Dyrk2^-/-^* MEFs using ARL13B as a cilia axoneme marker. Cilia lengths in EGFP- or AURKA-EGFP-positive cells are presented as pooled from three MEFs derived from independent *Dyrk2^-/-^* embryos (**F**) and represent an average of each MEF (**G**). Data are presented as the means ± SEM (*n* = 3 biological replicates per condition). The statistical significance between EGFP- and AURKA-EGFP-positive cells was determined by the Student's *t*-test. (\*\*) p\<0.01.\
Figure 9---source data 1.Source data for [Figure 9F and G](#fig9){ref-type="fig"}.](elife-57381-fig9){#fig9}

###### A list of downregulated or upregulated genes in Dyrk2^-/-^ MEFs

  ------------------------------------ ------------ ------------------------------------------------------------------------------------ --------------------------------------------------------- --------------------------------------------------------
  Down-regulated genes in Dyrk2^-/-^                                                                                                                                                               
  ID                                   GeneSymbol   Description                                                                          Ratio of Dyrk2^-/-^per wild-type in the presence of SAG   Ratio of Dyrk2^-/-^per wild-type in the absence of SAG
  ENSMUSG00000028630                   Dyrk2        Dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2                     0.02                                                      0.03
  ENSMUSG00000035683                   Melk         Maternal embryonic leucine zipper kinase                                             0.23                                                      0.22
  ENSMUSG00000074476                   Spc24        NDC80 kinetochore complex component%2C homolog (*S. cerevisiae*)                     0.25                                                      0.21
  ENSMUSG00000020808                   Pimreg       PICALM interacting mitotic regulator                                                 0.28                                                      0.28
  ENSMUSG00000033952                   Aspm         Abnormal spindle microtubule assembly                                                0.31                                                      0.25
  ENSMUSG00000026683                   Nuf2         NDC80 kinetochore complex component                                                  0.31                                                      0.30
  ENSMUSG00000037466                   Tedc1        Tubulin epsilon and delta complex 1                                                  0.31                                                      0.26
  ENSMUSG00000030867                   Plk1         Polo-like kinase 1                                                                   0.31                                                      0.17
  ENSMUSG00000022033                   Pbk          PDZ binding kinase                                                                   0.33                                                      0.29
  ENSMUSG00000027326                   Knl1         Kinetochore scaffold 1                                                               0.33                                                      0.20
  ENSMUSG00000041431                   Ccnb1        Cyclin B1                                                                            0.33                                                      0.26
  ENSMUSG00000036777                   Anln         Anillin actin binding protein                                                        0.33                                                      0.26
  ENSMUSG00000001403                   Ube2c        Ubiquitin-conjugating enzyme E2C                                                     0.33                                                      0.25
  ENSMUSG00000027496                   Aurka        Aurora kinase A                                                                      0.34                                                      0.26
  ENSMUSG00000001349                   Cnn1         Calponin 1                                                                           0.34                                                      0.31
  ENSMUSG00000032218                   Ccnb2        Cyclin B2                                                                            0.34                                                      0.28
  ENSMUSG00000026039                   Sgo2a        Shugoshin 2A                                                                         0.34                                                      0.25
  ENSMUSG00000015880                   Ncapg        Non-SMC condensin I complex subunit G                                                0.34                                                      0.34
  ENSMUSG00000027379                   Bub1         BUB1 mitotic checkpoint serine/threonine kinase                                      0.36                                                      0.23
  ENSMUSG00000040084                   Bub1b        BUB1B mitotic checkpoint serine/threonine kinase                                     0.36                                                      0.29
  ENSMUSG00000045328                   Cenpe        Centromere protein E                                                                 0.36                                                      0.22
  ENSMUSG00000032254                   Kif23        Kinesin family member 23                                                             0.37                                                      0.25
  ENSMUSG00000028873                   Cdca8        Cell division cycle associated 8                                                     0.37                                                      0.30
  ENSMUSG00000032135                   Mcam         Melanoma cell adhesion molecule                                                      0.37                                                      0.29
  ENSMUSG00000027469                   Tpx2         TPX2microtubule-associated                                                           0.37                                                      0.33
  ENSMUSG00000028678                   Kif2c        Kinesin family member 2C                                                             0.37                                                      0.24
  ENSMUSG00000027715                   Ccna2        Cyclin A2                                                                            0.38                                                      0.23
  ENSMUSG00000048327                   Ckap2l       Cytoskeleton associated protein 2-like                                               0.39                                                      0.23
  ENSMUSG00000040204                   Pclaf        PCNA clamp associated factor                                                         0.40                                                      0.19
  ENSMUSG00000029414                   Kntc1        Kinetochore associated 1                                                             0.42                                                      0.24
  ENSMUSG00000034311                   Kif4         Kinesin family member 4                                                              0.42                                                      0.24
  ENSMUSG00000031004                   Mki67        Antigen identified by monoclonal antibody Ki 67                                      0.42                                                      0.21
  ENSMUSG00000020914                   Top2a        Topoisomerase (DNA) II alpha                                                         0.42                                                      0.21
  ENSMUSG00000033031                   Cip2a        Cell proliferation regulating inhibitor of protein phosphatase 2A                    0.42                                                      0.32
  ENSMUSG00000035783                   Acta2        Actin alpha two smooth muscle aorta                                                  0.43                                                      0.48
  ENSMUSG00000024795                   Kif20b       Kinesin family member 20B                                                            0.43                                                      0.30
  ENSMUSG00000038943                   Prc1         Protein regulator of cytokinesis 1                                                   0.43                                                      0.26
  ENSMUSG00000026494                   Kif26b       Kinesin family member 26B                                                            0.43                                                      0.25
  ENSMUSG00000023015                   Racgap1      Rac GTPase-activating protein 1                                                      0.43                                                      0.26
  ENSMUSG00000026605                   Cenpf        Centromere protein F                                                                 0.44                                                      0.25
  ENSMUSG00000027306                   Nusap1       Nucleolar and spindle associated protein 1                                           0.45                                                      0.28
  ENSMUSG00000028068                   Iqgap3       IQ motif containing GTPase activating protein 3                                      0.46                                                      0.21
  ENSMUSG00000003779                   Kif20a       Kinesin family member 20A                                                            0.47                                                      0.25
  ENSMUSG00000005410                   Mcm5         Minichromosome maintenance complex component 5                                       0.47                                                      0.26
  ENSMUSG00000034906                   Ncaph        Non-SMC condensin I complex subunit H                                                0.47                                                      0.27
  ENSMUSG00000006398                   Cdc20        Cell division cycle 20                                                               0.48                                                      0.29
  ENSMUSG00000037313                   Tacc3        Transforming acidic coiled-coil containing protein 3                                 0.48                                                      0.36
  ENSMUSG00000027699                   Ect2         ect2 oncogene                                                                        0.48                                                      0.26
  ENSMUSG00000020330                   Hmmr         Hyaluronan-mediated motility receptor (RHAMM)                                        0.50                                                      0.28
  ENSMUSG00000020649                   Rrm2         Ribonucleotide reductase M2                                                          0.50                                                      0.26
  ENSMUSG00000019942                   Cdk1         Cyclin-dependent kinase 1                                                            0.50                                                      0.34
  ENSMUSG00000024590                   Lmnb1        Lamin B1                                                                             0.51                                                      0.33
  ENSMUSG00000037725                   Ckap2        Cytoskeleton associated protein 2                                                    0.55                                                      0.42
  Upregulated genes in Dyrk2^-/-^                                                                                                                                                                  
  ID                                   GeneSymbol   Description                                                                          Ratio of Dyrk2^-/-^per wild-type in the presence of SAG   Ratio of Dyrk2^-/-^per wild-type in the absence of SAG
  ENSMUSG00000056673                   Kdm5d        Lysine (K)-specific demethylase 5D                                                   Inf                                                       Inf
  ENSMUSG00000068457                   Uty          Ubiquitously transcribed tetratricopeptide repeat gene Y chromosome                  Inf                                                       Inf
  ENSMUSG00000069049                   Ddx3y        DEAD (Asp-Glu-Ala-Asp) box polypeptide 3 Y-linked                                    Inf                                                       8278
  ENSMUSG00000069045                   Eif2s3y      Eukaryotic translation initiation factor 2 subunit three structural gene Y-linked    Inf                                                       Inf
  ENSMUSG00000112616                   Gm47434      Predicted gene 47434                                                                 719                                                       Inf
  ENSMUSG00000025582                   Nptx1        Neuronal pentraxin 1                                                                 4.74                                                      11.91
  ENSMUSG00000024164                   C3           Complement component 3                                                               4.47                                                      11.59
  ENSMUSG00000039457                   Ppl          Periplakin                                                                           4.30                                                      11.11
  ENSMUSG00000025784                   Clec3b       C-type lectin domain family three member b                                           3.99                                                      8.60
  ENSMUSG00000002944                   Cd36         CD36 molecule                                                                        3.20                                                      3.45
  ENSMUSG00000035385                   Ccl2         Chemokine (C-C motif) ligand 2                                                       2.86                                                      2.84
  ENSMUSG00000095478                   Gm9824       Predicted pseudogene 9824                                                            2.60                                                      4.14
  ENSMUSG00000038642                   Ctss         Cathepsin S                                                                          2.58                                                      3.19
  ENSMUSG00000043719                   Col6a6       Collagen type VI alpha 6                                                             2.44                                                      4.64
  ENSMUSG00000033327                   Tnxb         Tenascin XB                                                                          2.37                                                      3.61
  ENSMUSG00000069516                   Lyz2         Lysozyme 2                                                                           2.30                                                      3.08
  ENSMUSG00000016494                   Cd34         CD34 antigen                                                                         2.29                                                      2.26
  ENSMUSG00000042129                   Rassf4       Ras association (RalGDS/AF-6) domain family member 4                                 2.29                                                      3.43
  ENSMUSG00000004730                   Adgre1       Adhesion G-protein-coupled receptor E1                                               2.27                                                      2.49
  ENSMUSG00000030144                   Clec4d       C-type lectin domain family member d                                                 2.26                                                      3.74
  ENSMUSG00000029816                   Gpnmb        Glycoprotein (transmembrane) nmb                                                     2.22                                                      2.66
  ENSMUSG00000042286                   Stab1        Stabilin 1                                                                           2.18                                                      2.70
  ENSMUSG00000020120                   Plek         Pleckstrin                                                                           2.18                                                      2.99
  ENSMUSG00000040254                   Sema3d       Sema domain immunoglobulin domain (Ig) short basic domain secreted (semaphorin) 3D   2.17                                                      2.89
  ENSMUSG00000005268                   Prlr         Prolactin receptor                                                                   2.17                                                      4.44
  ENSMUSG00000024621                   Csf1r        Colony-stimulating factor one receptor                                               2.10                                                      2.74
  ENSMUSG00000074896                   Ifit3        Interferon-induced protein with tetratricopeptide repeats 3                          2.04                                                      3.96
  ENSMUSG00000002985                   Apoe         Apolipoprotein E                                                                     2.03                                                      2.51
  ENSMUSG00000057137                   Tmem140      Transmembrane protein 140                                                            2.02                                                      3.18
  ENSMUSG00000002289                   Angptl4      Angiopoietin-like 4                                                                  2.02                                                      5.94
  ENSMUSG00000050335                   Lgals3       Lectin galactose binding soluble 3                                                   1.99                                                      2.66
  ENSMUSG00000090877                   Hspa1b       Heat-shock protein 1B                                                                1.98                                                      2.13
  ENSMUSG00000054404                   Slfn5        Schlafen 5                                                                           1.96                                                      3.77
  ENSMUSG00000031209                   Heph         Hephaestin                                                                           1.92                                                      2.48
  ENSMUSG00000027996                   Sfrp2        Secreted frizzled-related protein 2                                                  1.91                                                      5.68
  ENSMUSG00000050953                   Gja1         Gap junction protein alpha 1                                                         1.90                                                      2.45
  ENSMUSG00000005413                   Hmox1        Heme oxygenase 1                                                                     1.90                                                      1.97
  ENSMUSG00000046805                   Mpeg1        Macrophage expressed gene 1                                                          1.85                                                      2.57
  ENSMUSG00000022037                   Clu          Clusterin                                                                            1.83                                                      3.06
  ENSMUSG00000026389                   Steap3       STEAP family member 3                                                                1.81                                                      2.24
  ENSMUSG00000041577                   Prelp        Proline arginine-rich end leucine-rich repeat                                        1.81                                                      2.01
  ENSMUSG00000027339                   Rassf2       Ras association (RalGDS/AF-6) domain family member 2                                 1.80                                                      2.72
  ------------------------------------ ------------ ------------------------------------------------------------------------------------ --------------------------------------------------------- --------------------------------------------------------

These findings collectively support the potential mechanism that DYRK2 governs ciliogenesis by, at least in part, maintaining the expression of *Aurka* and other disassembly genes.

Discussion {#s3}
==========

DYRK2 is a positive regulator of Hh signaling {#s3-1}
---------------------------------------------

Although evidence indicates that DYRK2 plays important roles in the development of lower eukaryotes ([@bib40]; [@bib39]; [@bib26]), little is known regarding the functions of DYRK2 in mammalian development. In the present study, we demonstrate for the first time that DYRK2 is required for normal Hh signaling and embryogenesis in vivo. Varjosalo et al. have established a human full-length protein kinase cDNA and corresponding kinase activity-deficient mutant library, and they reported that DYRK2 functions as a negative regulator of Hh signaling via direct phosphorylation and induction of the proteasome-dependent degradation of GLIs using in vitro over-expression approaches ([@bib54]). In sharp contrast, our present study demonstrated using knockout approaches that endogenous protein levels of GLI2, and marginally the ratio of GLI3^REP^/GLI3^FL^, are decreased by deletion of *Dyrk2* in vitro after SAG-treatment. Consistently, *Dyrk2^-/-^* embryos exhibited some typical phenotypes of inactivation of Hh signaling in vivo as indicated by abnormal responses but not the elimination of ligands. Taken together with the observed loss of *Gli1* induction in *Dyrk2^-/-^* MEFs in vitro, we concluded that DYRK2 functions as a positive regulator of Hh signaling. GLI2 and GLI3, the key mediators of Hh signaling, are known to have specific and redundant functions ([@bib31]). In skeletal patterning during development, *Dyrk2^-/-^* embryos exhibit phenotypes that are more similar to those of double *Gli2* and *Gli3* mutants than to those of each single mutant. Conversely, the deletion of other indispensable upstream Hh components such as *Smo* ([@bib35]), *Ptch1 *([@bib48]), *Gpr161 *([@bib16]), and *SuFu *([@bib48]) results in more severe defects that occur at earlier embryonic stages. The present data do not rule out the possibility that DYRK2 directly regulates Hh components. Despite this, given the evidence that *Dyrk2^-/-^* embryos and cells possess morphological abnormalities in primary cilia, it is clear that DYRK2 plays a pivotal role in regulating Hh signaling via the control of ciliogenesis.

*Dyrk2* is a novel ciliogenesis-related gene in mice {#s3-2}
----------------------------------------------------

Intriguingly, we found that DYRK2 negatively regulates ciliogenesis. In *Chlamydomonas*, certain mutations that cause flagella to assemble to excessive length (i.e. negatively regulator of ciliogenesis) have been identified, and these include mutations in LF1 through LF5 ([@bib59]; [@bib52]). Among these, LF2, LF4, and LF5 encode protein kinases and are homologs of vertebrate CCRK, MAK/ICK/MOK, and CDKL5, respectively. In addition to these genes, GSK3β also negatively regulates cilia and flagella length ([@bib62]). Interestingly, DYRK2 belongs to the same kinase group as CCRK, MAK/ICK/MOK, CDKL5, and GSK3β (the CMGC group) ([@bib2]). To the best of our knowledge, however, the present study demonstrates for the first time that DYRK2 is a ciliogenesis-related gene and a negative regulator of ciliogenesis. Among these kinases, *Dyrk2^-/-^* embryos exhibit similar phenotypes to *Ick*-deletion mice in vivo such as skeletal defects and cilia morphology, although they do not possess a hydrocephalus defect ([@bib32]). In response to *Ick-* or *Mok-*knockdown, cilia length depends on the activation of mTORC1 signaling ([@bib3]). Our previous study reported the activation of mTORC1 signaling in *DYRK2-*knockdown human breast cancer cells ([@bib30]). As expected, mTORC1 signaling was slightly activated in *Dyrk2^-/-^* MEFs; however, rapamycin, an inhibitor of mTORC1, did not significantly affect cilia length in *Dyrk2^-/-^* MEFs. Thus, DYRK2 may control ciliogenesis through different mechanisms than those of other CMGC-kinases.

DYRK2 is required for ciliogenesis and the dynamic trafficking of Hedgehog components in cilia {#s3-3}
----------------------------------------------------------------------------------------------

Abnormal ciliary trafficking of Hh components causes dysfunction in Hh signaling in several types of mutant mice ([@bib12]; [@bib32]). *Dyrk2^-/-^* MEFs and embryos possessed disordered accumulation of Hh components (GLI2, GLI3, and SuFu) at cilia tips and exhibited elongation of cilia. On the other hand, SMO recruitment dependent on ligand stimulation was normally observed in *Dyrk2^-/-^* MEFs ([Figure 10](#fig10){ref-type="fig"}). Moreover, DYRK2 localizes at TZ, which acts as a selective barrier to control ciliary import and export of proteins ([@bib10]). Given the findings that ciliary localization and ciliary disorders were observed in *Dyrk2^-/-^* cells, DYRK2 could be involved in regulation of ciliary protein entry and exit. The functions of DYRK2 at TZ, however, remains to be elucidated.

![Schematic representation of DYRK2 in ciliogenesis and Hh signaling.\
(Left panel) A schematic model of normal ciliogenesis and response to stimulation with Hh ligand. (Right panel) A schematic model ciliogenesis and response to stimulation with Hh ligand in *Dyrk2*-deletion. The morphology of primary cilia in *Dyrk2^-/-^* MEFs was elongated and often bulged at the tips. In *Dyrk2^-/-^* cells, downregulation of *Aurka* and other ciliary disassembly genes caused suppression of disassembly and elongation of primary cilia. Furthermore, abnormal ciliary trafficking caused accumulation of GLI2, GLI3, and SuFu in *Dyrk2^-/-^* cells. Consequently, the induction of Hh signaling is drastically suppressed by deletion of *Dyrk2.*](elife-57381-fig10){#fig10}

As a first step to elucidate the functions of DYRK2 in cilia, we focused on factors involved in ciliary length control using a transcriptome approach, and we identified the downregulation of genes related to ciliary resorption mechanisms for proliferation in *Dyrk2^-/-^* MEFs, such as *Aurka*, *Plk1*, *Ube2c*, *Tpx2, Kif2c,* and *Cdc20*. Among these, AURKA has been well-characterized as a disassembly factor, as transient knockdown by siRNA or treatment with an inhibitor of AURKA completely blocked ciliary disassembly during proliferation ([@bib42]; [@bib18]). In contrast to ciliary disassembly under proliferation, the function of AURKA for controlling ciliary length at steady state is unclear. In the present study, transient knockdown of *Aurka* under serum-starvation conditions induced elongation of cilia in a manner similar to that observed in *Dyrk2^-/-^* MEFs. These data imply that the down-regulation of *Aurka* is, at least in part, associated with the phenotypes observed after deletion of *Dyrk2.* The expression of *Aurka* is known to be regulated by pathways such as YAP/TAZ ([@bib22]) and AKT signaling ([@bib41]). The molecular mechanisms underlying DYRK2-mediated *Aurka* regulation and ciliary trafficking remain unclear. Further research is required to elucidate these mechanisms.

A possible relationship between DYRK2 and human ciliopathy {#s3-4}
----------------------------------------------------------

A number of syndromes caused by disorders involving ciliary proteins are categorized as skeletal ciliopathies, and these include short-rib thoracic dysplasia (SRTD), Jeune asphyxiating thoracic dystrophy (JATD), orofaciodigital syndrome (OFD), Ellis-van Creveld syndrome (EVC), and cranioectodermal dysplasia (CED) ([@bib44]). In mice, deletion of *Dyrk2* induces morphological abnormalities in primary cilia and skeletal defects in vivo. Additionally, DYRK2 is a ciliary protein that is primarily localized at the basal body and the TZ, which contains a growing number of ciliopathy proteins ([@bib43]). While the present study does not include any evidence to support the relationship between DYRK2 and human disease, our results do suggest a possibility that *DYRK2* is involved in human ciliopathy, particularly in regard to skeletal disorders. Further investigations involving exome sequencing or genome-wide association studies using human patients will prove useful to clarify this issue.

Conclusion {#s3-5}
----------

In summary, we identified DYRK2 as a novel mammalian ciliogenesis-related gene in vivo and in vitro. Deletion of *Dyrk2* induces abnormal ciliary morphology and trafficking of Hh pathway components and suppresses Hh signaling during mouse embryogenesis. The abnormal ciliogenesis in *Dyrk2^-/-^* cells is partially caused by downregulation of *Aurka* and other disassembly genes. These findings will allow for a more complete understanding of the molecular mechanisms underlying embryogenesis, ciliogenesis, and human ciliopathy.

Materials and methods {#s4}
=====================

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\                           Designation                                                 Source or reference                                                                           Identifiers                                                                         Additional information
  (species) or resource                                                                                                                                                                                                                                                                 
  --------------------------------------- ----------------------------------------------------------- --------------------------------------------------------------------------------------------- ----------------------------------------------------------------------------------- -----------------------------------------------------------
  Genetic reagent (*M. musculus*)         *Dyrk2*^-/-^ mouse                                          This paper                                                                                    N/A                                                                                 Maintained in K. Yoshida lab.

  Cell line (*M. musculus*)               Wild-type and *Dyrk2*^-/-^ MEFs                             This paper                                                                                    N/A                                                                                 Maintained in K. Yoshida lab.

  Cell line (*H. sapiens*)                hTERT-RPE1                                                  ATCC                                                                                          Cat\# CRL-4000 RRID:[CVCL_4388](https://scicrunch.org/resolver/CVCL_4388)           

  Transfected construct (*M. musculus*)   mouse *Aurka*/pEGFP-C1                                      This paper                                                                                    N/A                                                                                 See Materials and methods subsection 'Plasmid constructs'

  Transfected construct (*M. musculus*)   mouse *Dyrk2*/FN22K-Halo Tag-CMVd1-Flexi-vector             This paper                                                                                    N/A                                                                                 See Materials and methods subsection 'Plasmid constructs'

  Transfected construct (*M. musculus*)   *Dyrk2* targeting vector                                    Knockout Mouse Project Repository                                                             PG00105_X\_1_G09, PG00105_X\_1_E04                                                  See Materials and methods subsection 'Plasmid constructs'

  Recombinant DNA regent                  Plasmid pEGFP-C1\                                           TaKaRa Bio                                                                                    Cat\# 6084--1                                                                       \
                                          (empty vector)                                                                                                                                                                                                                                \

  Recombinant DNA regent                  Plasmid pFN22K-Halo Tag-CMVd1-Flexi-vector (empty vector)   Promega                                                                                       Cat\# G2851                                                                         

  Transfected construct (*M. musculus*)   *Dyrk2* targeting vector                                    Knockout Mouse Project Repository                                                             PG00105_X\_1_G09, PG00105_X\_1_E04                                                  

  Biological sample (Adenovirus)          Adenovirus-*Cre*                                            [@bib60] doi: [10.1016/j.canlet.2019.02.046](https://doi.org/10.1016/j.canlet.2019.02.046).   N/A                                                                                 

  Biological sample (Adenovirus)          Adenovirus-human *DYRK2*                                    [@bib60] doi: [10.1016/j.canlet.2019.02.046](https://doi.org/10.1016/j.canlet.2019.02.046).   N/A                                                                                 

  Biological sample (Adenovirus)          Adenovirus-human *DYRK2-K251R*                              [@bib60] doi: [10.1016/j.canlet.2019.02.046](https://doi.org/10.1016/j.canlet.2019.02.046).   N/A                                                                                 

  Biological sample (Adenovirus)          Adenovirus-GFP                                              [@bib60] doi: [10.1016/j.canlet.2019.02.046](https://doi.org/10.1016/j.canlet.2019.02.046).   N/A                                                                                 

  Antibody                                Anti-Acetylated-tubulin (Mouse monoclonal)                  Sigma-Aldrich                                                                                 Cat\# T7451, RRID:[AB\_](https://scicrunch.org/resolver/AB_)609894                  ICC (1:2000)

  Antibody                                Anti-ARL13B (Mouse monoclonal)                              Abcam                                                                                         Cat\# ab136648,N/A                                                                  ICC (1:300)

  Antibody                                Anti-ARL13B (Rabbit polyclonal)                             Proteintech                                                                                   Cat\# 17711--1-AP, RRID:[AB_2060867](https://scicrunch.org/resolver/AB_2060867)     ICC (1:400)

  IHC (1:400)                                                                                                                                                                                                                                                                           

  Antibody                                Anti-AURKA (Mouse monoclonal)                               BD Transduction                                                                               Cat\# 610938, RRID:[AB_398251](https://scicrunch.org/resolver/AB_398251)            WB (1:1000)

  Antibody                                Anti-DYRK2 (Rabbit polyclonal)                              Sigma-Aldrich                                                                                 Cat\# HPA027230, RRID:[AB_1847925](https://scicrunch.org/resolver/AB_1847925)       WB (1:1000)

  ICC (1:400)                                                                                                                                                                                                                                                                           

  Antibody                                Anti-FOXA2 (Mouse monoclonal)                               Developmental Studies Hybridoma Bank                                                          Cat\# 4C7, RRID:[AB_528207](https://scicrunch.org/resolver/AB_528207)               IHC (1:8)

  Antibody                                Anti-CP110 (Rabbit polyclonal)                              Proteintech                                                                                   Cat\# 12780--1-AP, RRID:[AB_10638480](https://scicrunch.org/resolver/AB_10638480)   WB (1:1000)

  Antibody                                Anti-GAPDH (Mouse monoclonal)                               Santa Cruz Biotechnology                                                                      Cat\# sc-32233, RRID:[AB_627679](https://scicrunch.org/resolver/AB_627679)          WB (1:3000)

  Antibody                                Anti-GFP (Chicken polyclonal IgY)                           Aves Labs                                                                                     Cat\# GFP-1020, RRID:[AB_10000240](https://scicrunch.org/resolver/AB_10000240)      ICC (1:500)

  Antibody                                Anti-GFP (Rabbit monoclonal)                                Abcam                                                                                         Cat\# ab183734, RRID:[AB_2732027](https://scicrunch.org/resolver/AB_2732027)        WB (1:30000)

  Antibody                                Anti-GLI1 (Rabbit polyclonal)                               Cell Signaling Technology                                                                     Cat\# 2534, RRID:[AB_2294745](https://scicrunch.org/resolver/AB_2294745)            WB (1:500)

  ICC (1:100)                                                                                                                                                                                                                                                                           

  Antibody                                Anti-GLI2 (Goat polyclonal)                                 R and D systems                                                                               Cat\# AF3635, RRID:[AB_2111902](https://scicrunch.org/resolver/AB_2111902)          WB (1:500)

  ICC (1:50)                                                                                                                                                                                                                                                                            

  IHC (1:50)                                                                                                                                                                                                                                                                            

  Antibody                                Anti-GLI3 (Goat polyclonal)                                 R and D systems                                                                               Cat\# AF3690, RRID:[AB_2232499](https://scicrunch.org/resolver/AB_2232499)          WB (1:200)

  ICC (1:100)                                                                                                                                                                                                                                                                           

  IHC (1:150)                                                                                                                                                                                                                                                                           

  Antibody                                Anti-gamma-tubulin (Goat polyclonal)                        Santa Cruz Biotechnology                                                                      Cat\# sc-7396, RRID:[AB_2211262](https://scicrunch.org/resolver/AB_2211262)         ICC (1:3500)

  Antibody                                Anti-gamma-tubulin (Mouse monoclonal)                       Santa Cruz Biotechnology                                                                      Cat\# sc-17787, RRID:[AB_628417](https://scicrunch.org/resolver/AB_628417)          ICC (1:400)

  IHC (1:400)                                                                                                                                                                                                                                                                           

  Antibody                                Anti-HaloTag (Rabbit polyclonal)                            Promega                                                                                       Cat\# G9281, RRID:[AB_713650](https://scicrunch.org/resolver/AB_713650)             ICC (1:700)

  Antibody                                Anti-IFT140 (Rabbit polyclonal)                             Proteintech                                                                                   Cat\# 17460--1-AP, RRID:[AB_2295648](https://scicrunch.org/resolver/AB_2295648)     ICC (1:100)

  Antibody                                Anti-IFT81 (Rabbit polyclonal)                              Proteintech                                                                                   Cat\# 11744--1-AP, RRID:[AB_2121966](https://scicrunch.org/resolver/AB_2121966)     ICC (1:50)

  Antibody                                Anti-IFT88 (Rabbit polyclonal)                              Proteintech                                                                                   Cat\# 13967--1-AP, RRID:[AB_2121979](https://scicrunch.org/resolver/AB_2121979)     ICC (1:100)

  Antibody                                Anti-KATANIN p60 (Mouse monoclonal)                         Santa Cruz Biotechnology                                                                      Cat\# sc-373814, RRID:[AB_11014191](https://scicrunch.org/resolver/AB_11014191)     WB (1:1000)

  Antibody                                Anti-KI67 (Rabbit monoclonal)                               Abcam                                                                                         Cat\# ab16667, RRID:[AB_302459](https://scicrunch.org/resolver/AB_302459)           ICC (1:500)

  Antibody                                Anti-NPHP1 (Mouse monoclonal)                               SIGMA-Aldrich                                                                                 Cat\# MABS2185,N/A                                                                  ICC (1:100)

  Antibody                                Anti-mTORC1 (Rabbit monoclonal)                             Cell Signaling Technology                                                                     Cat\# 2972, RRID:[AB_330978](https://scicrunch.org/resolver/AB_330978)              WB (1:1000)

  Antibody                                Anti-NKX2.2 (Mouse monoclonal)                              Developmental Studies Hybridoma Bank                                                          Cat\# 74.5A5, RRID:[AB_531794](https://scicrunch.org/resolver/AB_531794)            IHC (1:10)

  Antibody                                Anti-NKX6.1 (Mouse monoclonal)                              Developmental Studies Hybridoma Bank                                                          Cat\# F55A10, RRID:[AB_532378](https://scicrunch.org/resolver/AB_532378)            IHC (1:100)

  Antibody                                Anti-OLIG2 (Rabbit monoclonal)                              abcam                                                                                         Cat\# ab109186, RRID:[AB_10861310](https://scicrunch.org/resolver/AB_10861310)      IHC (1:500)

  Antibody                                Anti-PAX6 (Mouse monoclonal)                                Santa Cruz Biotechnology                                                                      Cat\# sc-81649, RRID:[AB_1127044](https://scicrunch.org/resolver/AB_1127044)        IHC (1:400)

  Antibody                                Anti-Phosho-S6 (Ser 235/236) (Rabbit monoclonal)            Cell Signaling Technology                                                                     Cat\# 2211, RRID:[AB_331679](https://scicrunch.org/resolver/AB_331679)              WB (1:2000)

  Antibody                                Anti-P-4EBP1(Thr 37/46) (Rabbit monoclonal)                 Cell Signaling Technology                                                                     Cat\# 2855, RRID:[AB_560835](https://scicrunch.org/resolver/AB_560835)              WB (1:1500)

  Antibody                                Anti-SMO (Mouse monoclonal)                                 Santa Cruz Biotechnology                                                                      Cat\# sc-166685, RRID:[AB_2239686](https://scicrunch.org/resolver/AB_2239686)       ICC (1:100)

  Antibody                                Anti-SuFu (Mouse monoclonal)                                Santa Cruz Biotechnology                                                                      Cat\# sc-137014, RRID:[AB_2197315](https://scicrunch.org/resolver/AB_2197315)       ICC (1:100)

  Antibody                                Anti-S6 (Rabbit monoclonal)                                 Cell Signaling Technology                                                                     Cat\# 2217, RRID:[AB_331355](https://scicrunch.org/resolver/AB_331355)              WB (1:2000)

  Antibody                                Anti-4EBP1 (Rabbit monoclonal)                              Cell Signaling Technology                                                                     Cat\# 9644, RRID:[AB_2097841](https://scicrunch.org/resolver/AB_2097841)            WB (1:3000)

  Sequence-based reagent                  Human *DYRK2* siRNA\#1                                      BEX                                                                                           608481                                                                              

  Sequence-based reagent                  Human *DYRK2* siRNA\#2                                      ThermoFisher Scientific                                                                       HSS112284                                                                           

  Sequence-based reagent                  Mouse *Dyrk2* siRNA\#1                                      ThermoFisher Scientific                                                                       4390771 (s87545)                                                                    

  Sequence-based reagent                  Mouse *Dyrk2* siRNA\#2                                      ThermoFisher Scientific                                                                       4390771 (s87546)                                                                    

  Sequence-based reagent                  Mouse *Aurka* siRNA\#1                                      Integrated DNA Technologies                                                                   mm.Ri.Aurka.13.1                                                                    

  Sequence-based reagent                  Mouse *Aurka* siRNA\#2                                      Integrated DNA Technologies                                                                   mm.Ri.Aurka.13.4                                                                    

  Sequence-based reagent                  Mouse *Cdc20* siRNA                                         Integrated DNA Technologies                                                                   mm.Ri.Cdc20.13.2                                                                    

  Sequence-based reagent                  Mouse *Kif2c* siRNA                                         Integrated DNA Technologies                                                                   mm.Ri.Kif2c.13.3                                                                    

  Sequence-based reagent                  Mouse *Plk1* siRNA                                          Integrated DNA Technologies                                                                   mm.Ri.Plk1.13.1                                                                     

  Sequence-based reagent                  Mouse *Tpx2* siRNA                                          Integrated DNA Technologies                                                                   mm.Ri.Tpx2.13.1                                                                     

  Sequence-based reagent                  Mouse *Ube2c* siRNA                                         Integrated DNA Technologies                                                                   mm.Ri.Ube2c.13.1                                                                    

  Sequence-based reagent                  Negative Control DsiRNA (siNegative)                        Integrated DNA Technologies                                                                   51-01-14                                                                            

  Sequence-based reagent                  Silencer Select Negative Control (siControl)                ThermoFisher Scientific                                                                       4390843                                                                             

  Chemical compound, drug                 InSolution SAG                                              Merck                                                                                         566660                                                                              

  Chemical compound, drug                 Rapamycin                                                   LC Laboratories                                                                               R-5000                                                                              

  Software, algorithm                     BZ-X800 Analyzer                                            Keyence                                                                                       BZ-X800 Analyzer                                                                    

  Software, algorithm                     Excel                                                       Microsoft                                                                                     Mac2019                                                                             

  Software, algorithm                     Fusion                                                      M and S Instruments                                                                           Fusion                                                                              

  Software, algorithm                     GraphPad Prism 7                                            GraphPad Software Inc                                                                         Mac OS X                                                                            

  Software, algorithm                     PikoReal Software 2.1                                       ThermoFisher Scientific                                                                       PikoReal Software 2.1                                                               
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Generation of *Dyrk2* knockout mice (*Dyrk2^-/-^*) {#s4-1}
--------------------------------------------------

*Dyrk2^-/-^* mice were generated using the knockout-first strategy ([@bib46]). A schematic representation of the targeted *Dyrk2* allele is provided in [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}. The *Dyrk2* targeting vector (PG00105_X\_1_G09 and PG00105_X\_1_E04) was obtained from the Knockout Mouse Project Repository (*Dyrk2* targeting project: 337--66440). Gene-targeting methods were performed according to standard protocols. Briefly, linearized vectors were electroporated into JM8A3.N1 embryonic stem (ES) cells. G418-resistant ES cell clones were analyzed using Southern blot analysis for the presence of the correct targeted-allele using BglII digestion and a 3' external probe. Hybridization with the 3' external probe detected 10.7 kb (wild-type allele) and 17.0 kb (targeted tm1a allele) BglII bands ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). Six positive ES clones out of 240 clones were obtained. Chimeric mice were created by injection of the targeted ES cells into C57BL/6J blastocysts and were mated with C57BL/6J WT mice to establish germline-transmitted founders. Heterozygous knockout-first (*Dyrk2*^tm1a^) mice were identified using Southern blotting. An exon three knockout allele (*Dyrk2*^tm1b^) was generated by mating the *Dyrk2*^tm1a^ mice the with CAG-Cre mice ([Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). For genotyping and validation of knockout alleles, we performed PCR using the primers listed in [Table 2](#table2){ref-type="table"}.

###### List of primer sets.

  -------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------
  For genotyping                                                                                                                                                                 
  Gene                                                                             Sequence (5\'→3\')                             Accession number                               
  *Dyrk2 tm1b-WT*                                                                  Forward                                        TGGGTCCAAATGCAAAGAAACGCCA                      NC_000076.6
  Reverse                                                                          GCTTCTCGTTCCGCACCATCTTCAG                                                                     
  *Dyrk2 tm1b-KO*                                                                  Forward                                        CCTTCTCCCTCCTCCACTCTGACCCA                     NC_000076.6
  Reverse                                                                          CCACACCTCCCCCTGAACCTGAAAC                                                                     
  For amplification of the probes for in situ hybridization or Southern blotting                                                                                                 
  Gene                                                                             Sequence (5\'→3\')                             Accession number                               
  Mouse *Foxf2*                                                                    Forward                                        GAGATTAACCCTCACTAAAGGGAGGTTATGGTGGCCTCGACAT    NM_010225.2
  Reverse                                                                          GAGTAATACGACTCACTATAGGGACACACACACCTCCCTTTTCA                                                  
  Mouse *Gli1*                                                                     Forward                                        GAGTATTTAGGTGACACTATAGAAGCAGGGAAGAGAGCAGACTG   NM_010296.2
  Reverse                                                                          GAGTAATACGACTCACTATAGGGGCTGAGTGTTGTCCAGGTC                                                    
  Mouse *Ptch1*                                                                    Forward                                        GAGATTAACCCTCACTAAAGGGACATGGCCTCGGCTGGTAAC     NM_008957.3
  Reverse                                                                          GAGTAATACGACTCACTATAGGGTGTACCCATGGCCAACTTCG                                                   
  Southern for *Dyrk2*                                                             Forward                                        CTTCGAATCCTTTTATCCTTCAGGC                      NC_000076.6
  Reverse                                                                          ACATCATGTTCATTGGTTTTGCTCT                                                                     
  For cloning                                                                                                                                                                    
  Gene                                                                             Sequence (5\'→3\')                             Accession number                               
  Mouse *Aurka CDS*                                                                Forward                                        GGACTCAGATCTCGAGACATGGCTGTTGAGGGCG             NM_011497.4
  Reverse                                                                          GTCGACTGCAGAATTCCTAAGATGATTTGCTGGTTG                                                          
  Mouse *Dyrk2 CDS*                                                                Forward                                        GTGCGCGATCGCCATGTTAACCAGGAAACCTTCGGC           NM_001014390.2
  Reverse                                                                          CTCCGTTTAAACGCTAACGAGTTTCGGCAACAC                                                             
  For real-time PCR                                                                                                                                                              
  Gene                                                                             Sequence (5\'→3\')                             Accession number                               
  Human *DYRK2*                                                                    Forward                                        GGGGAGAAAACGTCAGTGAA                           NM_006482.3
  Reverse                                                                          TCTGCGCCAAATTAGTCCTC                                                                          
  Human *HPRT1*                                                                    Forward                                        GGACTAATTATGGACAGGACTG                         NM_000194.3
  Reverse                                                                          GCTCTTCAGTCTGATAAAATCTAC                                                                      
  Mouse *Aurka*                                                                    Forward                                        CACACGTACCAGGAGACTTACAGA                       NM_011497.4
  Reverse                                                                          AGTCTTGAAATGAGGTCCCTGGCT                                                                      
  Mouse *Cdc20*                                                                    Forward                                        GAGCTCAAAGGACACACAGC                           NM_023223.2
  Reverse                                                                          GCCACAACCGTAGAGTCTCA                                                                          
  Mouse *Dyrk2*                                                                    Forward                                        CTACCACTACAGCCCACACG                           NM_001014390.2
  Reverse                                                                          TCTGTCCGTGGCTGTTGA                                                                            
  Mouse *Foxf2*                                                                    Forward                                        AGCATGTCTTCCTACTCGTTG                          NM_010225.2
  Reverse                                                                          TCTTTCCTGTCGCACACT                                                                            
  Mouse *Gli1*                                                                     Forward                                        GCACCACATCAACAGTGAGC                           NM_010296.2
  Reverse                                                                          GCGTCTTGAGGTTTTCAAGG                                                                          
  Mouse *Hprt*                                                                     Forward                                        CTCATGGACTGATTATGGACAGGAC                      NM_013556.2
  Reverse                                                                          GCAGGTCAGCAAAGAACTTATAGCC                                                                     
  Mouse *Kif2c*                                                                    Forward                                        GAGAGCAAGCTGACCCAGG                            NM_134471.4
  Reverse                                                                          CCTGGTGAGATCATGGCGATC                                                                         
  Mouse *Plk1*                                                                     Forward                                        CCAAGCACATCAACCCAGTG                           NM_011121.4
  Reverse                                                                          TGAGGCAGGTAATAGGGAGACG                                                                        
  Mouse *Ptch1*                                                                    Forward                                        CTCTGGAGCAGATTTCCAAGG                          NM_008957.3
  Reverse                                                                          TGCCGCAGTTCTTTTGAATG                                                                          
  Mouse *Shh*                                                                      Forward                                        GTGAAGCTGCGAGTGACCG                            NM_009170.3
  Reverse                                                                          CCTGGTCGTCAGCCGCCAGCACGC                                                                      
  Mouse *Tpx2*                                                                     Forward                                        GCGAGGTTGTCAGGTGTGTA                           NM_001141977.1
  Reverse                                                                          TTGATAAAGTCGGTGGGGGC                                                                          
  Mouse *Ube2c*                                                                    Forward                                        CTGCTAGGAGAACCCAACATC                          NM_026785.2
  Reverse                                                                          GCTGGAGACCTGCTTTGAATA                                                                         
  -------------------------------------------------------------------------------- ---------------------------------------------- ---------------------------------------------- ----------------

Animal care {#s4-2}
-----------

Mice were housed individually in a temperature-controlled room under a 12 hr light/dark cycle. Determination of pregnancy in mice was achieved by the observation of a vaginal plug on day 0.5 of gestation. Animals were euthanized by anesthesia. The animal experiment protocol was approved by the Institutional Animal Care and Use Committee of Jikei University (No. 2017--065 and 2018--031), and the studies were performed in accordance with the Guidelines for the Proper Conduct of Animal Experiments of the Science Council of Japan.

Alcian blue and alizarin red staining {#s4-3}
-------------------------------------

Euthanized wild-type and *Dyrk2^-/-^* mice at E18.5 and E16.5 were skinned, eviscerated, and fixed in 100% EtOH. For skeletal analysis, the embryos were stained with 1% Alcian Blue (Wako Pure Chemicals, Osaka, Japan) dissolved in 20% glacial acetic acid and 80% EtOH and 0.01% Alizarin Red (Sigma-Aldrich, St. Louis, MO) dissolved in 1% KOH. The excised tissues were observed using a stereo microscope (BioTools, Gunma, Japan). Ten embryos of each wild-type and *Dyrk2^-/-^* mice were analyzed.

In situ hybridization {#s4-4}
---------------------

In situ hybridization was performed according to a previous report ([@bib9]). Briefly, each digoxigenin (DIG)-labeled cRNA probe was amplified by PCR using primer sets ([Table 2](#table2){ref-type="table"}) and labeled using the Roche DIG RNA labeling kit (Merck, Schwalbach, Germany). Embryos at E10.5 and the heads of mice at E14.5 were fixed using MEMFA (2 mM EGTA, 1 mM MgSO4, and 3.7% formaldehyde) in 100 mM MOPS (pH 7.5) overnight at 4°C, and this was followed by immersion in 30% trehalose (Wako) in 20 mM HEPES to cryoprotect the tissues. Cryosections (7 μm thickness) from the transverse or sagittal plane were hybridized with DIG-labeled cRNA probe and were visualized with alkaline phosphatase-conjugated anti-DIG antibody (Merck) using 4-nitroblue tetrazolium chloride (NBT; Merck) and 5-bromo-4-chloro-3-indolyl phosphate (BCIP; Merck). The sections were observed under a BZ-X800 microscope (KEYENCE, Osaka, Japan).

Immunohistochemistry and hematoxylin and eosin (HE)-staining {#s4-5}
------------------------------------------------------------

Embryos at E10.5, E13.5, and E18.5 were fixed and sliced as described above. Depending on the antibody, the sections were antigen retrieved by an ImmunoSaver (Nisshin EM, Tokyo, Japan) for 60 min at 80°C. The sections were incubated with 10% (v/v) fetal bovine serum and 0.4% (v/v) Triton X-100 in HEPES buffer (blocking buffer). After washing, the sections were incubated with primary antibodies (Key resources table) in blocking buffer at 4°C overnight. After the immunoreaction, the sections were incubated with secondary antibodies using Cy3-, Cy5-, or FITC-conjugated AffiniPure donkey anti-goat, rabbit, and mouse IgG (Jackson ImmunoResearch, West Grove, PA). The sections were washed and incubated in VECTASHIELD Mounting Medium (Vector Laboratories, Burlingame, CA) containing 4,6′-diamidino-2-phenylindole dihydrochloride (DAPI). For HE-staining, the sections were stained using standard procedures. The sections were observed under a BZ-X800 fluorescence microscope (KEYENCE).

Scanning electron microscopy (SEM) {#s4-6}
----------------------------------

Wild-type and *Dyrk2^-/-^* embryos at E10.5 were washed with 0.1 M phosphate buffer (PB) (pH7.5) and fixed with 2% glutaraldehyde (TAAB Laboratories Equipment, Berkshire, England) in 0.1 M PB (pH 7.4) for 1 week at 4°C. The embryos were placed in tannic acid in 0.1 M PB for 2 hr at room temperature in darkness, and then immersed in 1% OsO~4~ solution for 2 hr at room temperature. After dehydration in graded ethanol, the samples were transferred into isoamyl acetate and dried at the critical point in liquid CO~2~, and this was followed by a metal coating procedure (Hitachi, Tokyo, Japan). The surfaces of tissues were then observed using scanning electron microscopy (Hitachi).

Plasmid constructs {#s4-7}
------------------

Full-length cDNA fragments of mouse *Dyrk2* and *Aurka* were amplified by PCR and cloned in frame into the pFN22K-HaloTag-CMVd1-Flexi-vector (Promega, Madison, WI) and pEGFP-C1 (TaKaRa Bio, Otsu, Japan), respectively. The nucleotide sequences of the primers used are listed in [Table 2](#table2){ref-type="table"}.

Cell culture and transfection {#s4-8}
-----------------------------

Primary mouse embryonic fibroblast (MEFs) were generated from wild-type and *Dyrk2^-/-^* embryos at E13.5. MEFs and immortalized human retinal pigment epithelia cells (hTERT-RPE1; Cat\# CRL-4000, RRID:[CVCL_4388](https://scicrunch.org/resolver/CVCL_4388), ATCC, Manassas, VA) were cultured in DMEM (nacalai tesque, Kyoto, Japan) with 10% FBS (biowest, Nuaille, France), 1% GultaMAX (Gibco, Gaithersburg, MD), and 1% Penicillin-streptomycin (nacalai tesque) at 37°C under 5% CO~2~. hTERT-RPE1 cells were authenticated by the STR profiling and negative for mycoplasma contamination. To induce ciliogenesis, cells were grown to 80--90% confluency and serum-starved (0.5% FBS) for 24 hr. For SAG-stimulation, cells were treated with 100 nM SAG (Merck) for 24 hr after serum-starvation. For rapamycin-stimulation, cells were treated with 0.5 µM rapamycin (LC Laboratories, Woburn, MA) for 24 hr after serum-starvation. Transient knockdown was achieved using the Lipofectamine RNAiMAX transfection regent (ThermoFisher Scientific, Waltham, MA) for 48 hr under serum-starvation conditions according to the manufacturer's instructions with a final concentration of 6--20 nM siRNA (Key resources table). For over-expression of DYRK2-HaloTag, transfection was performed using X-tremeGENE9 (Merck) for hTERT-RPE1 cells according to the manufacturer's instructions and the cells were cultured for 24 hr under serum-starvation condition for ciliogenesis. For over-expression of AURKA-EGFP or EGFP, transfection was performed using Xfect (TaKaRa Bio) for MEFs according to the manufacturer's instructions, and the cells were cultured for 24 hr under serum-starvation condition for ciliogenesis.

Adenovirus infection {#s4-9}
--------------------

Adenovirus construction and infections were performed according to a previous report ([@bib28]; [@bib60]). Briefly, Flag-DYRK2 and Flag-DYRK2-K251R ([@bib50]; [@bib29]) were expressed depending upon *Cre*-expression. Following infection at a MOI (multiplicity of infection) of 100, MEFs were extracted for gene-expression analysis at 60 hr post-infection. MOI for MEFs was determined using an adenovirus construct for GFP-expression.

Immunoblotting {#s4-10}
--------------

Tissues (the limb buds at E13.5) and MEFs were washed in twice and lysed using RIPA buffer containing several inhibitors (1 mM PMSF, 10 µg/ml Aprotinin, 1 µg/ml Leupeptin, 1 µg/ml Pepstatin A, 1 mM Na~3~VO~4~, 10 mM NaF, and 1 mM DTT). Equal amounts of protein (5 µg) were resolved on 4--15% Mini-PROTEA TGX Precast Protein Gels (BioRad, Hercules, CA). After electrophoresis, proteins were transferred to PVDF membranes (Merck). Membranes were blocked with 5% skim milk in tris-buffered saline (TBS) containing 0.05% Tween 20 (TBST) or 0.1% casein/gelatin in TBST, depending on the antibody. Primary and secondary antibodies were reacted in each blocking buffer (Key resources table). Signals were detected using a chemiluminescent regent, ImmunoStar LD (Wako). Signals were observed and band intensity was measured using a Fusion-Solo system (M and S Instruments, Tokyo, Japan).

Quantitative real-time polymerase chain reaction (qPCR) {#s4-11}
-------------------------------------------------------

Total RNAs were prepared from tissues (the limbs of E13.5, the mandibular arches of E10.5, and whole embryos at E9.5) and MEFs using the RNeasy mini kit (QIAGEN, Germantown, MD) or ISOGEN II (Nippon Gene, Tokyo, Japan), respectively. Reverse transcripts were obtained using PrimeScript Reverse Transcriptase (TaKaRa Bio) and subjected to qPCR using a PIKOREAL96 system (ThermoFisher Scientific). Reactions were performed in KAPA SYBR FAST qPCR Master Mix (NIPPON Genetics, Tokyo, Japan) that included 0.2 μM of a specific primer set for each gene ([Table 2](#table2){ref-type="table"}). Data were calculated by the comparative C~T~ method (ΔC~T~ method) to estimate the mRNA copy number relative to that of *Hprt* as an internal standard. The DNA sequence of the PCR product was confirmed by nucleotide sequencing (data not shown).

Immunocytochemistry {#s4-12}
-------------------

For immunocytochemistry, MEFs and hTERT-RPE1 cells were cultured on 8-well chamber slides (ThermoFisher Scientific) coated with Poly-D-lysin (Sigma-Aldrich). Cells were fixed and antigen retrieved depending on the antibody. The primary antibody reaction was performed at an appropriate dilution (Key resources table) in the presence of blocking buffer at 4°C overnight. After immunoreactions, cells were incubated with secondary antibodies using Cy3-, Cy5-, or FITC-conjugated AffiniPure donkey anti-goat, rabbit, and mouse IgG, and chicken IgY (Jackson ImmunoResearch). The cells were then washed and incubated with DAPI. Immunofluorescence was observed under a BZ-X800 fluorescence microscope (KEYENCE).

RNA-Seq {#s4-13}
-------

Total RNAs were prepared from MEFs cultured in the absence or presence of 100 nM SAG for 24 hr using RNeasy mini kit (QIAGEN) with DNase I treatment (QIAGEN). Materials were enriched for polyA sequences, and quantitative RNA-sequencing was performed using an Illumina HiSeq (Illumina, San Diego, CA). Cutadapt v1.9.1 was used to trim and filter reads, and clean data were aligned to the reference genome (ENSEMBLE, GRCm38.97) using the software HISAT 2 (v2.0.1). Relative gene expression was quantified and normalized in a FPKM (fragments per kilobase of transcript per million mapped reads) format.

STRING and gene ontology (GO) analysis {#s4-14}
--------------------------------------

To determine the presence of interactions/partnerships among downregulated genes in *Dyrk2^-/-^* MEFs, protein-protein interaction networks were extracted from the STRING database (<https://string-db.org>) and drawn by STRING v11. Gene ontology (GO) analysis was also performed using STRING v11 to demonstrate the biological processes enriched in the altered genes. The resulting GO terms that possessed a false discovery rate (FDR) of less than 0.005 were considered as enriched biological processes.

Statistical analysis {#s4-15}
--------------------

Each experiment was confirmed by at least three independent biological replicates per condition. Data are presented as the means ± SEM. Prism seven software (GraphPad, San Diego, CA, USA) was used for statistical analyses. Means between two groups were compared using the Student's *t*-test. Multiple inter-group differences were analyzed by one-way ANOVA (analysis of variance) followed by Tukey's multiple comparison test.
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Decision letter

Pedersen

Lotte

Reviewing Editor

University of Copenhagen

Denmark

In the interests of transparency, eLife publishes the most substantive revision requests and the accompanying author responses.

Thank you for submitting your article \"The novel ciliogenesis regulator DYRK2 governs Hedgehog signaling during mouse embryogenesis\" for consideration by *eLife*. Your article has been reviewed by three peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by Piali Sengupta as the Senior Editor. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

As the editors have judged that your manuscript is of interest, but as described below that additional experiments are required before it is published, we would like to draw your attention to changes in our revision policy that we have made in response to COVID-19 (https://elifesciences.org/articles/57162). First, because many researchers have temporarily lost access to the labs, we will give authors as much time as they need to submit revised manuscripts. We are also offering, if you choose, to post the manuscript to bioRxiv (if it is not already there) along with this decision letter and a formal designation that the manuscript is \"in revision at *eLife*\". Please let us know if you would like to pursue this option. (If your work is more suitable for medRxiv, you will need to post the preprint yourself, as the mechanisms for us to do so are still in development.)

Summary:

Yoshida et al. characterize the phenotype of *Dyrk2* mutant mice, and show that loss of this kinase results in reduced Hh signaling both in vivo and in cells derived from the *Dyrk2^-/-^* embryos. They also show that *Dyrk2^-/-^* embryos and MEFs have ciliary defects- primarily longer cilia with abnormal tips, and defects in the trafficking of Hh components *Gli2* and *Gli3*. *Dyrk2* is postulated to localize to transition zone of cilia and regulate transcription of AurA, which the authors propose as the mechanism underlying ciliary length changes.

The data presented are robust and thorough. The authors are recognized leaders in understanding the role of *Dyrk2* in cancer pathways and in DNA damage response through phosphorylation of diverse substrates including p53 and c-Jun/Myc. They now highlight a completely novel role of this kinase in embryonic development as a regulator of ciliary morphology and Hh signaling. *Dyrk2* has also been postulated to act as scaffold for EDVP complex in proteolysis of substrates such as the centrosome protein CP110 and microtubule severing enzyme, Katanin. The authors now convincingly show a role of *Dyrk2* as a positive regulator of Hh pathway by careful knockout studies during mouse embryogenesis in the context of craniofacial and skeletal development and Hh signaling assays in vitro. These results are in stark contrast to a previously published paper using *Dyrk2* overexpression that proposed a negative regulatory role of *Dyrk2* in Hh pathway through *Gli2* and Gli3 degradation and direct phosphorylation of *Gli2* at two residues (S385, S1011) (PMID: 18455992). Despite the nicely demonstrated broad role of this kinase in Hh signaling and late embryogenesis, the mechanism proposed for this postulated transition zone-localized protein in causing ciliary dysmorphology through AurA kinase transcription is unclear. Therefore, this work presents interesting findings and is generally well-performed and merits publication, though there are some additional experiments and/or questions to address that could improve the work considerably.

Essential revisions:

1\) The authors show low Hh signaling by ISH/qRT PCR of Hh pathway targets in craniofacial region and limbs at e13.5. The later skeletal abnormalities are consistent with Hh signaling defects (although no polydactyly is seen). However, no neural tube patterning defects are seen. Considering that cilia length abnormalities are seen at E10.5 (earlier stages have not been looked at), and *Gli2/3/*SuFu are accumulated in MEF cilia irrespective of *Smo* activation, it is surprising that the Hh signaling defects are not observed in earlier stages of development. The neural tube development defects are shown to be unaffected only at the branchial level at E10.5. The authors should at least test total RNA levels of Hh pathway targets in early stage embryos and rule out dorsoventral patterning defects at earlier stages.

2\) The phenotypes of the *Dyrk2^-/-^* mice as described seem to be fairly limited to bone growth and differentiation (and also neural crest-derived craniofacial structures). This certainly points to a role for Hh signaling, but could indicate that the phenotype is tissue specific. Is *Dyrk2* expression tissue restricted? If so this would be very interesting since it would point to *Dyrk2* being a tissue-specific regulator of cilia. Few proteins that regulate cilia in a cell type-specific manner have been identified and little is known about how such regulation is achieved. Making this link might increase the impact of the paper, if it is the case.

3\) The localization of *Dyrk2* in transition zone and/or centrosome should be better documented using transition zone markers and necessary controls for the antibody using ko MEFs.

4\) The accumulation of *Gli2*/*3* in resting MEF cilia (but not of *Smo*) is similar to PKA null MEFs (PMID: 22007132), which in contrast show high Hh signaling. Here, an alternative hypothesis regarding *Dyrk2* function such as its role in affecting turnaround in ciliary tips and/or affecting axonemal architecture through its function as a kinase for *Gli2* and/or EDVP complex scaffold, respectively might be considered.

5\) A more thorough characterization of the ciliary defects in the *Dyrk2^-/-^* cells is desirable. Primarily, what happens to cilia frequency in *Dyrk2^-/-^* cells? If cilia frequency is not affected in these mutants, this would not detract from the work or the conclusions of the paper, but it is important to know the answer. They should also assess whether cilia frequency in cycling *Dyrk2^-/-^* MEFs is different- it seems possible loss of this kinase might increase cilia frequency when few cilia are typically present, especially given that they find that *AurkA* expression is reduced in the mutant cells. Again, it would just be interesting to know this either way.

6\) The potential mechanism by which DYRK2 regulates ciliary length is insufficiently discussed/addressed in this study. First of all, the Introduction needs to provide a more thorough and accurate description of the literature relevant for ciliary length control and disassembly, as well as a clear description of what the differences are between steady state ciliary length control and ciliary disassembly observed e.g. during serum re-addition to starved cultures of mammalian cells. Second, the authors suggest that one potential mechanism by which DYRK2 negatively regulates ciliary length is by controlling expression of key cilia disassembly factors such as AURKA, but it is unclear why a transcriptomics approach was used in the first place. Moreover, the observed changes in the transcriptome could be a consequence rather than a cause of the long cilia phenotype seen in DYRK2 deficient cells. Therefore, a rescue experiment that shows normal ciliary length of DYRK2 mutant cells when AURKA expression is normalized must be provided if the authors want to claim that altered AURKA levels are responsible for the phenotype. DYRK2 is a kinase that the authors show is concentrated near the ciliary base; previous work implicated the EDVP complex in regulation of katanin (PMID: 19287380) and CP110 proteolysis (PMID: 28242748). CP110 is a key regulator of ciliogenesis also implicated in ciliary length control, thus an obvious question to ask is what happens to CP110 (centrosomal) levels in cells lacking DYRK2. This experiment should be fairly easy to do as good antibodies against CP110 are commercially available. Katanin levels could be analysed similarly.

7\) Subsection "*Dyrk2* deficiency cause suppression of Hedgehog signaling during mouse embryogenesis" and Figure 1: Some quantitative analysis is missing here. How many embryos/animals were examined?

8\) Figure 3D: What is the relative expression levels of the wild type and mutant DYRK2 protein in these experiments and are the transfection efficiencies similar for both constructs? This is important to know in order to rule out that the observed difference in rescue effect of the two constructs is not simply due to different cellular expression level. Also, kinase-dead *Dyrk2* does restore significant levels of *Ptch1* transcript with respect to wild-type. Statistical significance for *Gli1* levels is not mentioned with respect to wild-type. *Dyrk2* could have kinase-independent functions as a scaffold.

9\) Subsection "DYRK2 regulates ciliogenesis" and Figure 5---figure supplement 3: without quantification the data is not very meaningful, so either the data needs to be quantified or alternatively removed.

10\) The manuscript contains several grammatical errors and typos that need to be corrected to enhance readability and clarity.

10.7554/eLife.57381.sa2

Author response

Essential revisions:

> 1\) The authors show low Hh signaling by ISH/qRT PCR of Hh pathway targets in craniofacial region and limbs at e13.5. The later skeletal abnormalities are consistent with Hh signaling defects (although no polydactyly is seen). However, no neural tube patterning defects are seen. Considering that cilia length abnormalities are seen at E10.5 (earlier stages have not been looked at), and *Gli2/3/*SuFu are accumulated in MEF cilia irrespective of *Smo* activation, it is surprising that the Hh signaling defects are not observed in earlier stages of development. The neural tube development defects are shown to be unaffected only at the branchial level at E10.5. The authors should at least test total RNA levels of Hh pathway targets in early stage embryos and rule out dorsoventral patterning defects at earlier stages.

As requested, we performed qPCR of Hh target genes using cDNA from whole embryo at E9.5. The results demonstrated a repression of *Gli1* (p=0.077), *Ptch1* (p\<0.01), and *Foxf2* (p\<0.01) in *Dyrk2^-/-^* embryos newly prepared Figure 2---figure supplement 1B. These data clearly show the defect in Hh signaling in *Dyrk2^-/-^*mice at early stage embryos (E9.5).

To further confirm this finding, we performed in situ hybridization for *Ptch1* at E10.5 newly prepared Figure 2---figure supplement 1C. The results demonstrated that *Ptch1*-expression was decreased in several regions such as the mandibular arch in *Dyrk2^-/-^* embryos, but remained unchanged in the neural tube. Based on these data, we concluded that Hh signaling is active state at the neural tube in *Dyrk2^-/-^* embryos.

Additionally, we speculate that these data have relation to a spatiotemporal expression-pattern of *Dyrk2* in embryo we also commented below (Essential revisions comment 2).

According to the reviewer's comment, we added newly prepared Figure 2---figure supplement 1B and Figure 2---figure supplement 1C, and their figure legends.

In addition, we added Figure 2---figure supplement 1---source data 1.

We also revised the following sentences in the revised text:

Results: subsection "*Dyrk2* deficiency cause suppression of Hedgehog signaling during mouse embryogenesis", third paragraph.

Materials and methods: subsection "In situ hybridization" and subsection "Quantitative real-time polymerase chain reaction (qPCR)".

Table 2: We added information of a primer set for *Ptch1*-probe.

> 2\) The phenotypes of the *Dyrk2^-/-^* mice as described seem to be fairly limited to bone growth and differentiation (and also neural crest-derived craniofacial structures). This certainly points to a role for Hh signaling, but could indicate that the phenotype is tissue specific. Is *Dyrk2* expression tissue restricted? If so this would be very interesting since it would point to *Dyrk2* being a tissue-specific regulator of cilia. Few proteins that regulate cilia in a cell type-specific manner have been identified and little is known about how such regulation is achieved. Making this link might increase the impact of the paper, if it is the case.

We appreciate your important suggestion and really agree with your comment.

We have tried to identify the localization of DYRK2 using wild-type and *Dyrk2^-/-^* embryos by immunohistochemistry and in situ hybridization. Indeed, we have performed the immunohistochemistry using almost all commercially available antibodies against DYRK2 (more than 15 antibodies). In addition, we have tried to develop original antibodies using two independent epitopes.

Although we have also verified various conditions (e.g. fixation- and antigen retrieved-conditions using cryo-, frozen-, and paraffin-sections), we could not successfully detect specific immuno-positive signals (i.e. detecting only wild-type but not *Dyrk2^-/-^* embryos). We have also performed in situ hybridization using several probes for *Dyrk2*; however, we could not obtain positive results.

We would thus argue that, in the future, we would like to try to show it in a separate study.

> 3\) The localization of *Dyrk2* in transition zone and/or centrosome should be better documented using transition zone markers and necessary controls for the antibody using ko MEFs.

As suggested, we performed immunocytostaining for a TZ marker, NPHP1, in hTERT-RPE1 cells transfected with DYRK2-Halo vector. The results demonstrated that DYRK2-Halo-tag-positive signals are co-localized in NPHP1-positive signals newly prepared Figure 5D.

We analyzed the cellular localization of DYRK2 using hTERT-RPE1 cells overexpressed DYRK2-Halo vector, because we could not find available anti-DYRK2 antibodies to detect endogenous DYRK2 by immunocytostaining. Therefore, we performed a control experiment for anti-Halo tag and DYRK2 antibody in hTERT-RPE1 cells transfected with "empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector)". The results indicated that no signal was observed newly prepared Figure 5C.

Accordingly, we added newly prepared Figure 5C and D and their figure legends.

We also added the following sentences in the revised text: "No signal for anti-HaloTag (Figure 5C) or anti-DYRK2 (data not shown) was observed in hTERT-RPE1 cells transfected with empty vector (pFN22K-Halo Tag-CMVd1-Flexi-vector). Moreover, immuno-positive signals for DYRK2-HaloTag were co-localized with a TZ marker, NPHP1 (Figure 5D)".

We added information of anti-NPHP1 antibody and pFN22K-Halo Tag-CMVd1-Flexi-vector (empty vector) in Key Resources Table.

> 4\) The accumulation of *Gli2/3* in resting MEF cilia (but not of *Smo*) is similar to PKA null MEFs (PMID: 22007132), which in contrast show high Hh signaling. Here, an alternative hypothesis regarding *Dyrk2* function such as its role in affecting turnaround in ciliary tips and/or affecting axonemal architecture through its function as a kinase for *Gli2* and/or EDVP complex scaffold, respectively might be considered.

Thank you for your important suggestion. As our response to Essential revisions comment 6, to identify DYRK2's substrate involving in ciliogenesis, we have analyzed protein levels of CP110 and KATANIN p60, which are postulated as DYRK2's substrates, in *Dyrk2^-/-^*MEFs. The results showed no obvious difference between wild-type and *Dyrk2^-/-^*MEFs in these proteins newly prepared Figure 6---figure supplement 4.

While we are now trying to identify novel substrates of DYRK2 for ciliogenesis, we need more time to accomplish. In this context, we would like to show it in a separate study regarding the identification of novel substrates of DYRK2 involving in ciliogenesis.

Accordingly, we added newly prepared Figure 6---figure supplement 4 and its figure legend.

We also added the following sentence in the revised text: "Moreover, a centrosome protein CP110 ,(Maddika and Chen 2009) and a microtubule severing enzyme, KATANIN p60 et al.,(Hossain 2017), have been identified as substrates of DYRK2 for proteolysis. In *Dyrk2^-/-^* MEFs, however, no obvious difference in protein levels of both CP110 and KATANIN p60 was observed (Figure 6---figure supplement 4)".

We added information of anti-CP110 and KATANIN p60 antibodies in Key Resources Table.

> 5\) A more thorough characterization of the ciliary defects in the *Dyrk2^-/-^* cells is desirable. Primarily, what happens to cilia frequency in *Dyrk2*^*-/*-^ cells? If cilia frequency is not affected in these mutants, this would not detract from the work or the conclusions of the paper, but it is important to know the answer. They should also assess whether cilia frequency in cycling *Dyrk2^-/-^* MEFs is different- it seems possible loss of this kinase might increase cilia frequency when few cilia are typically present, especially given that they find that *AurkA* expression is reduced in the mutant cells. Again, it would just be interesting to know this either way.

According to the reviewer's comment, we measured the proportion of ciliated cells newly prepared Figure 4---figure supplement 3A-B, and confirmed no difference between wild-type and *Dyrk2^-/-^*MEFs.

We also analyzed the proportion of ciliated cells in cell cycling wild-type and *Dyrk2^-/-^*MEFs using KI67-staining newly prepared Figure 4---figure supplement 3C. The results showed that both wild-type and *Dyrk2^-/-^*MEFs in KI67-positive cells were hardly ciliated.

We also added the following sentences in the revised text: "In contrast to the length and morphology of primary cilia, no difference was observed on the proportion of ciliated cells in wild-type and *Dyrk2^-/-^*MEFs (Figure 4---figure supplement 3A-B). Similarly, in cell-cycling (KI67-positive) wild-type and *Dyrk2^-/-^*MEFs, there was comparable in the proportion of ciliated cells (ciliated cells in KI67-positive cells is 1 per 199 and 1 per 139 cells in wild-type and *Dyrk2^-/-^*MEFs, respectively) (Figure 4---figure supplement 3C)".

We added Figure 4---figure supplement 3---source data 1, and information of anti-KI67 and ARL13B (abcam) antibodies in Key Resources Table.

> 6\) The potential mechanism by which DYRK2 regulates ciliary length is insufficiently discussed/addressed in this study. First of all, the Introduction needs to provide a more thorough and accurate description of the literature relevant for ciliary length control and disassembly, as well as a clear description of what the differences are between steady state ciliary length control and ciliary disassembly observed e.g. during serum re-addition to starved cultures of mammalian cells.

As indicated, we revised the third paragraph of the Introduction.

> Second, the authors suggest that one potential mechanism by which DYRK2 negatively regulates ciliary length is by controlling expression of key cilia disassembly factors such as AURKA, but it is unclear why a transcriptomics approach was used in the first place. Moreover, the observed changes in the transcriptome could be a consequence rather than a cause of the long cilia phenotype seen in DYRK2 deficient cells. Therefore, a rescue experiment that shows normal ciliary length of DYRK2 mutant cells when AURKA expression is normalized must be provided if the authors want to claim that altered AURKA levels are responsible for the phenotype. DYRK2 is a kinase that the authors show is concentrated near the ciliary base; previous work implicated the EDVP complex in regulation of katanin (PMID: 19287380) and CP110 proteolysis (PMID: 28242748). CP110 is a key regulator of ciliogenesis also implicated in ciliary length control, thus an obvious question to ask is what happens to CP110 (centrosomal) levels in cells lacking DYRK2. This experiment should be fairly easy to do as good antibodies against CP110 are commercially available. Katanin levels could be analysed similarly.

First of all, we have also focused on and analyzed protein levels of CP110 and KATANIN p60, which are postulated as DYRK2's substrates. Immuno-blotting of CP110 and KATANIN p60, however, showed no obvious difference between wild-type and *Dyrk2^-/-^*MEFs newly prepared Figure 6---figure supplement 4.

Therefore, to understand the phenotype of *Dyrk2^-/-^* cells in ciliogenesis in more detail and find novel clues, we performed transcriptome analysis.

Second, we performed a rescue experiment by over-expression of AURKA-EGFP in *Dyrk2^-/-^*MEFs newly prepared Figure 9. We observed a reduction of the cilia length in AURKA-EGFP-transfected *Dyrk2^-/-^* MEFs, but not in EGFP-transfected *Dyrk2^-/-^* MEFs. These data support that downregulated *Aurka-*expression is, at least in part, associated with phenotypes of *Dyrk2^-/^*^-^ cells.

Accordingly, we revised following points,

Related to CP110 and KATANIN p60:

We added newly prepared Figure 6---figure supplement 4 and its figure legend.

We also revised the text subsection "Deletion of DYRK2 induces abnormal ciliary trafficking of Hedgehog pathway components", last paragraph.

We added information of anti-CP110 and KATANIN p60 antibody in Key Resources Table.

Related to a rescue experiment of AURKA:

We added new data newly prepared Figure 9 and its figure legend.

In addition, we added Figure 9---source data 1.

We also revised the following sentences in the revised text:

Results: subsection "Deletion of *Dyrk2* dysregulates the expression of *Aurka* and other cilia-disassembly genes", end of first paragraph.

Materials and methods: subsection "Plasmid constructs", subsection "Cell culture and transfection", and subsection "Immunocytochemistry".

Table 2: We added information of a primer set for mouse *Aurka* CDS.

We added information of expression vector (mouse *Aurka*/pEGFP-C1 and pEGFP-C1) anti-GFP antibodies in Key Resources Table.

> 7\) Subsection "*Dyrk2* deficiency cause suppression of Hedgehog signaling during mouse embryogenesis" and Figure 1: Some quantitative analysis is missing here. How many embryos/animals were examined?

According to the reviewer's comment, we added the sentence: "Ten embryos of each wild-type and *Dyrk2^-/-^* mice were analyzed".

> 8\) Figure 3D: What is the relative expression levels of the wild type and mutant DYRK2 protein in these experiments and are the transfection efficiencies similar for both constructs? This is important to know in order to rule out that the observed difference in rescue effect of the two constructs is not simply due to different cellular expression level.

We added the immune-blotting data showing over-expression protein levels newly prepared Figure 3---figure supplement 1D and its figure legend, and confirmed that both WT and *K251R* were expressed with equal levels.

Additionally, to describe a method for determination of MOI, we added the following sentence "MOI for MEFs was determined using an adenovirus construct for GFP-expression" in the revised text, and information of an adenovirus for GFP-expression in Key Resources Table.

> Also, kinase-dead *Dyrk2* does restore significant levels of *Ptch1* transcript with respect to wild-type. Statistical significance for *Gli1* levels is not mentioned with respect to wild-type. *Dyrk2* could have kinase-independent functions as a scaffold.

First, we added the *P*-value "p=0.254" in Figure 3D. As pointed out, kinase-dead DYRK2 (*K251R*) showed a moderate effect for expression of *Gli1* and *Ptch1*. We consider that these data show a kinase independent function of DYRK2 (e.g. as scaffold protein, as the reviewers pointed out). Therefore, we added the following sentences "Additionally, over-expression of the *K251R* construct slightly increased *Gli1* and *Ptch1* expression in comparison with that of empty vector (Figure 3D). This kinase-independent effect might be associated with a function of DYRK2 as a scaffold protein Maddika and Chen, 2009".

> 9\) Subsection "DYRK2 regulates ciliogenesis" and Figure 5---figure supplement 3: without quantification the data is not very meaningful, so either the data needs to be quantified or alternatively removed.

According to the reviewer's comment, we removed the data Original Figure 5---figure supplement 3: Stability of primary cilia in *Dyrk2^-/-^*MEFs. Accordingly, we deleted the following sentences from the revised text: "Although we confirmed the acetylated and glutamylated tubulin modifications in the axoneme that are associated with stability of microtubules ,(Janke and Bulinski 2011), both modifications remained unchanged in *Dyrk2^-/-^*MEFs cilia according to immunostaining. Additionally, destabilization of axonemal microtubules induced by exposure to 4 °C et al.,(He 2014) showed no difference in loss of acetylated tubulin modification compared to that observed in wild-type".

We also deleted an information of anti-Glutamylated tubulin antibody from Key Resources Table.

> 10\) The manuscript contains several grammatical errors and typos that need to be corrected to enhance readability and clarity.

As requested, we carefully checked grammatical errors and typos throughout the revised manuscript and appropriately revised.
